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1 Abstract 
In a cat (#261) that had ostensibly recovered from experimental feline leukemia virus 
(FeLV) infection, we observed virus reappearance associated with development of B-
cell lymphoma. The virus variants found in this cat had largely replaced the original 
virus strain (FeLV-A/Glasgow-1) and had heavily mutated env genes and long 
terminal repeats (LTR). The goals of this study were to characterize the virus variants 
for viral fitness and host range and determine proviral integration sites. FeLV-
A/Glasgow-1 was sequenced and chimeric viruses containing env or LTR of the 
progeny viruses were constructed. The recombinant viruses showed lower or similar 
replication efficiency in feline embryonic fibroblasts (FEA cells) compared to FeLV-
A/Glasgow-1 when FeLV p27 antigen but less so when viral RNA was quantified. The 
host range of the FeLV-A/261env variant was ecotropic confirming the FeLV-A 
subgroup. Using genome walking, integration sites of the progeny proviruses in cat 
#261 and a second FeLV-A/Glasgow-1 infected cat with a T-cell lymphoma analyzed 
for comparison were found near genes that may contribute to neoplastic 
transformation (i.e. GFI1B, NAIF1, NKX2-2, PAX1, NKX2-1). All integration sites 
were distinct from common integration sites described so far in FeLV-infected cats as 
well as distinct between the two cats. This is the first study to document integration 
sites of FeLV-A/Glasgow-1 and progeny viruses thereof. 
 
Keywords: FeLV, FeLV-A variants, host range, replication efficiency, integration sites  
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2 Zusammenfassung 
Eine mit dem felinen Leukämievirus (FeLV) infizierte Katze (#261) mit regressivem 
Infektionsverlauf, zeigte eine Reaktivierung der Infektion und die Entwicklung eines 
B-Zell Lymphoms. Die auftretenden Virusvarianten hatten das ursprüngliche Virus 
(FeLV-A/Glasgow-1) beinahe vollständig ersetzt und zeigten ungewöhnlich viele 
Mutationen im Hüllprotein (env)-Gen und den Long Terminal Repeats (LTRs). Das 
Ziel dieser Studie war die Replikationsfähigkeit, das Wirtsspektrum und die 
Integrationsstellen der Virusvarianten zu charakterisieren. Dazu wurde FeLV-
A/Glasgow-1 sequenziert und Virus-Chimären mit env und LTRs der Varianten 
hergestellt. Die rekombinanten Viren zeigten eine im Vergleich zu FeLV-A/Glasgow-1 
schwächere oder vergleichbare Replikationsfähigkeit in felinen embryonalen 
Fibroblasten (FEA Zellen), v.a. wenn p27-Antigen und etwas weniger, wenn virale 
RNA gemessen wurde. Das Wirtsspektrum der rekombinanten FeLV-A/261env war 
ecotrop, was die Zugehörigkeit dieser Variante zur FeLV-A Untergruppe bestätigte. 
Mithilfe der „Genome Walking“ Methode wurden die Integrationsstellen bei der Katze 
#261 und einer zweiten FeLV-A/Glasgow-1 infizierten Katze mit einem T-Zell 
Lymphom in der Nähe von potentiell mit Tumorgenese assoziierten Genen lokalisiert 
(GFI1B, NAIF1, NKX2-2, PAX1, NKX2-1). Alle Integrationsstellen sind erstmals 
beschrieben und unterscheiden sich zwischen beiden Katzen. Die Studie 
demonstriert erstmals Integrationsstellen von FeLV-A/Glasgow-1 und Varianten 
dieses Virus. 
 
Schlüsselwörter: FeLV, FeLV-A Varianten, Wirtsspektrum, Replikationsfähigkeit, 
Integrationsstellen 
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3 Introduction 
Feline leukemia virus (FeLV) is a virus found in domestic cats and other felids, such 
as the Iberian lynx, Florida panther and captive born jaguarundis (Meli et al., 2009, 
Brown et al., 2008, Cunningham et al., 2008, Filoni et al., 2012, Luaces et al., 2008).  
FeLV is part of the retrovirus family and grouped in the genus gammaretrovirus 
together with retroviruses of rodents (e.g. MuLV), gibbons (GaLV) and koalas (KoRV).  
Jarrett et al. first described the virus in a study about transmissible leukemia (Jarrett 
et al., 1964b, Jarrett et al., 1964a).  
 
	
Figure 1: Genomic organization of FeLV provirus. Adapted from (Maetzig et al., 
2011). For explanation of the indicated abbreviations see text. 
 
Figure 1 shows the proviral genomic structure of FeLV containing three open reading 
frames (ORFs: gag, pol and env), which are flanked by the 5’ and 3’ long terminal 
repeats (LTR). The gag (group-specific antigen) gene is translated into a polyprotein 
Pr65gag, which is the precursor of the structural proteins; the matrix (MA or p15), the 
p12 (probably involved in the integration process), the capsid (CA or p27) and the 
nucleocapsid (NC or p10). The pol (polymerase) encodes the viral enzymes, being 
the protease (PR), the reverse transcriptase (RT) and the integrase (IN). The env 
(envelope) gene encodes the glycoproteins surface unit (SU or gp70) and the 
transmembrane (TM or p15E) domains. The LTRs are part of the non-coding region 
of the genome and are separated into the U3 (unique 3’ region), R (repeat region) 
and U5 (unique 5’ region). U3 contains the enhancer (E) and the promotor (P). In the 
viral genomic RNA both LTRs are incomplete, without the U3 but with a capping at 
the 5’ side and without the U5 but a poly-A tail at the 3’ side. LTRs are completed 
during the reverse transcription process. Other non-coding RNA regions are the 
primer binding site (PBS), the splice donor (SD), the packaging signal (Ψ), the splice 
acceptor (SA) and the polypurine tract (PPT).  
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The retroviral replication cycle begins with the attachment of the envelope 
glycoproteins to a host cell receptor followed by a membrane fusion releasing the 
virion core into the host cell. In the cytoplasm the enzyme reverse transcriptase starts 
to transcribe the dimeric RNA strand into double stranded DNA (dsDNA), which is 
transported into the cell nucleus. With the help of a second enzyme, the integrase, 
this dsDNA is integrated into the host cell genome as a provirus. From the integrated 
provirus viral RNA is expressed either in spliced or unspliced form. The splicing of 
the viral RNA results in subgenomic RNAs from which env proteins are translated. 
The unspliced viral RNA serves as a template for translation of gag and pol and also 
for whole genome replication. Fusion proteins of gag and pol (termed Pr65gag) are 
transported to the plasma membrane, polymerize together and are thought to interact 
with the membrane phospholipids via an N-terminal myristylation (Rein et al., 1986). 
Co-localized gag proteins (Felsenstein and Goff, 1988), transmembrane env proteins 
interact with the polymerized Pr65gag proteins. The packaging process of the dimeric 
virus RNA is started by its packaging signal (Ψ) and interaction with the Pr65gag 
complex. An immature virus particle is formed, which buds from the plasma 
membrane acquiring the membrane bilayer interspersed with env glycoproteins. 
Maturation into an infectious virus is induced by a viral protease cleaving the 
Pr65gag into its components, which then form the matrix (MA), capsid (CA) and 
nucleocapsid (NC) (Yoshinaka et al., 1985).  
There are different outcomes of infection and not every cat exposed to FeLV 
develops clinical signs. The majority of FeLV-exposed cats react with an effective 
immune response, leading to a regressive or even abortive infection with transient or 
undetectable viremia (Flynn et al., 2002). The regressive infection is often followed 
by a latent nonproductive nonviremic infection, where the virus persists in the 
genomic DNA of the host cells embedded as a provirus. If those provirus-positive 
cats are unable to maintain protective immunity, for example due to severe 
immunosuppression, the reemergence of the virus may occur; this is often paralleled 
by development of malignancies. This pathomechanism was shown in studies 
addressing FeLV reactivation after immunosuppression (Rojko et al., 1982, Pedersen 
et al., 1984, Hofmann-Lehmann et al., 2007). In some cats humoral and cellular 
immunity against FeLV is insufficient from the start of infection and a persistent 
viremia develops. Those cats with so-called progressive infection will succumb to 
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FeLV-associated diseases over a time course of several weeks to a few years 
(Hoover and Mullins, 1991, Hartmann, 2011).  
There are several FeLV subgroups defined based on their differences in host cell 
receptor usage and interference capabilities (Sarma and Log, 1973), which have a 
direct impact on clinical characteristics.  
FeLV-A is the main infectious agent and is transmitted through saliva, feces and 
blood among susceptible felids (Gomes-Keller et al., 2009, Francis et al., 1977). In 
experimental studies FeLV-A is strongly associated with thymic lymphoma of T-cell 
origin developed after a progressive infection for up to four years during which no 
clinical signs were observed (Rohn et al., 1994, Phipps et al., 2000). FeLV-A utilizes 
the thiamine transporter THTR1 as a receptor (Mendoza et al., 2006, Shalev et al., 
2009). All other FeLV subgroups arise from either recombination of FeLV-A with 
endogenous gamma retrovirus sequences (enFeLV, ERV-DC) or mutations in the 
FeLV-A env gene. FeLV-B (Stewart et al., 1986, Overbaugh et al., 1988b) and the 
more recently discovered FeLV-D (Ito et al., 2015) arise from recombination with 
endogenous retrovirus enFeLV or ERV-DC, respectively. In case of FeLV-B, this 
recombination leads to acquisition of enFeLV sequences encoding proteins of the 
surface unit (SU), which alter the receptor usage from THTR1 to Pit1 or Pit2 (both 
genes are part of the Solute Carrier Family 20 encoding phosphate symporter 
proteins) (Takeuchi et al., 1992, Boomer et al., 1997). Changes of receptor usage 
have an influence on cell tropism and host range. While FeLV-A has an ecotropic 
host range and therefore is only able to infect feline cell lines, the altered receptor 
usage of FeLV-B expands its host range and the virus, thus, is able to infect a variety 
of mammalian cell lines including human cell lines (Shojima et al., 2006, Nakata et al., 
2003). Receptors and host range for FeLV-D have not yet been identified (Ito et al., 
2015). 
FeLV-C and FeLV-T are formed by mutations (Neil et al., 1991, Donahue et al., 
1991). FeLV-C utilizes the heme exporter FLVCR1 as a receptor (Quigley et al., 2000, 
Tailor et al., 1999). Since FeLV-C is only found in anemic cats it is thought that the 
binding of the env protein to the FLVCR1 receptor disrupts its function preventing 
early erythropoiesis and consequently leads to a red blood cell aplasia (Onions et al., 
1982, Dornsife et al., 1989, Rey et al., 2008a, Quigley et al., 2004). FeLV-T is a 
fusion defective variant of FeLV that depends on a soluble co-factor, termed FELIX, 
for cell entry. This co-factor is primarily expressed by T-cells and derives from 
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enFeLV. It resembles the SU protein from subgroup FeLV-B, which also utilizes the 
Pit1 receptor (Anderson et al., 2000). FeLV-T causes severe immunosuppression in 
cats (Overbaugh et al., 1988a, Anderson et al., 2000, Sakaguchi et al., 2015). 
The occurrence of neoplasia is very common in FeLV-infected cats and has to do 
with the ability of the virus to integrate itself into the host’s genomic DNA. The 
mechanism is also described as retroviral insertional mutagenesis. If the retrovirus 
integrates near a proto-oncogene or an oncogene itself the promotor and enhancer 
function of the LTR can upregulate the gene expression and lead to tumorigenesis 
(Johnson et al., 2005). Another possible way of inducing tumors is integration into 
and thereby altering or disrupting a gene that is responsible for tumor prevention. In 
mice, this mechanism was instrumental in finding over a hundred loci of proto-
oncogenes in murine retrovirus induced tumors and in finding genes that were 
closely related to these retroviral insertions. These sites were termed as common 
integration sites (CIS). The detection of the c-myc gene as a CIS in murine (MuLV) 
and avian leucosis (ALV) led also to the investigation and discovery of this gene as a 
CIS in FeLV induced lymphomas (Neil et al., 1984, Forrest et al., 1987, Miura et al., 
1987, Miura et al., 1989). Other FeLV-integration loci include flvi-1, flvi-2 (bmi-1), fit-1, 
flit-1 and pim-1 (Tsatsanis et al., 1994, Levy et al., 1993, Levy and Lobelle-Rich, 
1992, Levesque et al., 1990, Tsujimoto et al., 1993, Fujino et al., 2009).  
In earlier studies, it was reported that up to 80% of the diagnosed lymphomas and 
leukemias were associated with FeLV (Francis et al., 1977, Francis et al., 1979, 
Hardy et al., 1980). Those percentages are decreasing though (Reinacher and 
Theilen, 1987, Moore et al., 1996, Teske et al., 2002, Stutzer et al., 2011) and one 
main reason is probably the decreasing prevalence of FeLV infection, which in turn is 
assigned to efficient FeLV diagnosis-removal programs and the development of 
efficacious FeLV vaccines (Cotter et al., 1975, Louwerens et al., 2005, Lutz et al., 
2009, Meichner et al., 2012). In 1984 the first commercially available FeLV vaccine 
was brought to the market in the USA. The step to develop an effective vaccine was 
of great interest not only for the cat population but also in sight of the possibility of 
new findings for HIV research.  
This thesis is a follow up study on the paper “Dominance of highly divergent feline 
leukemia virus a progeny variants in a cat with recurrent viremia and fatal 
lymphoma“ by A Katrin Helfer-Hungerbuehler and co-workers (Helfer-Hungerbuehler 
et al., 2010). This study reported the case of cat #261, a female SPF cat, which was 
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infected with FIV and vaccinated against FeLV prior to an experimental FeLV-
A/Glasgow-1 infection. The FeLV-viremia in this cat was only transient; thereafter, 
during later infection no antigen could be detected anymore by p27 antigen ELISA 
although the cat was provirus positive as assessed by a	nested FeLV PCR assay 
(Hofmann-Lehmann et al., 2001). The reappearance of FeLV viremia was observed 
8.5 years after the initial infection with FeLV-A/Glasgow-1 and was associated with 
immunosuppression (CD4+ T cell depletion) due to the pre- and co-existing infection 
with FIV. The cat developed a multicentric FeLV-positive lymphoma and was 
euthanized. By characterizing the progeny viruses it was discovered that the virus 
variants found in this cat had largely replaced the inoculation strain and had 
unusually heavily mutated envelopes and LTRs. In sight of the commonly highly 
conserved nature of FeLV-A strains these highly mutated virus variants were of 
special interest in terms of viral properties and replication behavior.  
The goal of this thesis was thus to characterize the virus progeny variants that arose 
in cat #261 by assessing the viral fitness and the host range of these viruses in vitro 
in comparison with the original inoculation prototype strain FeLV-A/Glasgow-1 and to 
determine the viral insertion sites of FeLV-A/Glasgow-1 and its progeny variants. 
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4 Materials and Methods 
4.1 Animal samples 
Tissues provided for this study derived from two specified pathogen-free (SPF) cats. 
Both cats were kept under barrier conditions and group housed according to the 
Swiss law and optimal ethological and hygienic conditions as previously described 
(Geret et al., 2011). All experiments were officially approved by the veterinary office 
of the canton of Zurich (197/89, 43/90, 66/91, 131/91, 329/91, 56/95, 59/2005). 
Cat #261 was a female SPF cat (Ciba Geigy, Basel, Switzerland) infected with a 
Swiss isolate of feline immunodeficiency virus (FIV) at the age of 17 weeks 
(Lehmann et al., 1991) and vaccinated with a recombinant FeLV p45 protein vaccine 
(Leucogen, Virbac, Nice, France) at the age of 41 weeks, revaccinated twice at the 
age of four years. In between, with 59 weeks, the cat was exposed intraperitoneally 
to FeLV-A/Glasgow-1 and developed a transient FeLV viremia but was then FeLV 
antigen and viral RNA negative until FeLV reappeared at the cat’s age of 9.6 years 
(Lehmann et al., 1991). The cat was co-housed with FeLV p27-positive cats during 
the first seven years post infection, after which it was kept with only p27-negative 
cats. At the time of necropsy, a multicentric FeLV-positive lymphoma categorized as 
a monoclonal proliferation of B cells was found (Helfer-Hungerbuehler et al., 2010). 
Histopathological examination was performed and samples from 27 tissues were 
collected, snap-frozen in liquid nitrogen and stored at -80°C.  
For the purpose of this study, tissues of the sternal lymph node, kidney, spleen and 
duodenum were used, all of which had previously been identified as part of the 
multicentric lymphoma.  
The cat #67 was part of a FeLV vaccination study (Hofmann-Lehmann et al., 2006) 
and turned FeLV-positive after exposure to FeLV-A/Glasgow-1. The cat remained 
persistently FeLV-positive (progressive infection). After developing a malignant T-cell 
lymphoma in thymus, spleen, liver and bone marrow, the cat was euthanized at the 
age of three years and underwent histopathological examination at which tissue 
samples were collected, snap-frozen in liquid nitrogen and stored at -80°C. For the 
purpose of this study, tumor tissue from the mediastinal lymph nodes and tissues of 
kidney, spleen and duodenum were used.  
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4.2 Nucleic acid extraction and cDNA production 
Genomic DNA was extracted using the QIAgen DNeasy® Blood & Tissue Kit (Qiagen, 
Hombrechtikon, Switzerland) from tissues of the cats #261 and #67. Viral RNA from 
cell culture supernatant was extracted using the MagNA Pure LC RNA Isolation Kit - 
High Performance (Roche Diagnostics GmbH, Mannheim). Negative extraction 
controls consisting of phosphate buffered saline (PBS 10x, without Ca2+ and Mg2+, 
Life Technologies™) were included with each extraction batch (Helfer-Hungerbuehler 
et al., 2010). Reverse transcription of RNA into cDNA was performed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Rotkreuz, 
Switzerland).  
 
4.3 Serological assays 
The level of FeLV antigenemia was determined by p27 antigen sandwich ELISA as 
described (Lutz et al., 1983). Values above 4% of the positive control run with each 
assay were considered positive (Hofmann-Lehmann et al., 2006).  
 
4.4 FeLV integration site detection from tumor DNA  
Genomic DNA from the sternal lymph node (very high provirus load of the env 
variants) of cat #261 and tumor tissue of cat #67 were prepared for screening of 
FeLV integration sites using the Universal GenomeWalker2.0 kit (Clontech 
Laboratories, Mountain View, CA) as described in the manufacturer’s user manual. 
Briefly, tumor DNA was digested with restriction enzymes DraI, EcoRV, PvuII or StuI 
to create four different DNA libraries. GenomeWalker adaptors were ligated to the 
different libraries DNA. A nested PCR was performed by using primers provided by 
Clontech, which bind to the GenomeWalker adaptor and specific primers, which bind 
to our area of interest, the FeLV LTR. Due to the widespread presence of 
endogenous FeLV in the cat genome, the method for the detection of CIS was 
adapted for the specific detection of only exogenous FeLV. For the PvuII and EcoRV 
libraries the primers used for the primary PCR were AP1 (Clontech) and GWLTR3’-
GSP1 (5’-GAG GCC AAG AAC AGT TAA ACC CCG GAT ATA G-3’) and for the 
nested PCR AP2 (Clontech) and GWLTR3’-GSP2 (5’-CTA ACC AAT CCC CAC GCC 
TCT CGC TTC TG-3’). The DraI and StuI libraries were amplified using AP1 and AP2 
PCR primers (Clontech) and GWLT5’-GSP3 (5’-AAA TGA GGC GGA AGG TCG 
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AAC TCT GG-3’) for the primary PCR and GWLT5’-GSP4 (5’-GGG TTT AAC TGT 
TCT TGG CCT CAA GC-3’) for the nested PCR. For primary PCRs the conditions 
were as follows: 1 cycle of 94°C for 15 s, 7 cycles of 94°C for 25 s followed by 72°C 
for 3 min, 32 cycles of 94°C for 25 s followed by 67°C for 3 min and 67°C for an 
additional 7 min after the last cycle. Conditions for secondary PCR: 1 cycle of 94°C 
for 15 s, 5 cycles of 94°C for 25 s followed by 72°C for 3 min, 20 cycles of 94°C for 
25 s followed by 67°C for 3 min and 67°C for an additional 7 min after the last cycle.  
Purified PCR products (NucleoSpin® Gel and PCR Clean-up, Macherey-Nagel, 
Clontech, Saint-Germain-en-Laye, France) were either directly sent for sequencing 
(Microsynth, Balgach, Switzerland) or prepared for cloning. Three to five PCR 
products of every restriction site library were taken and ligated into pCR®4-TOPO® 
Vector (TOPO TA® Cloning kit, Invitrogen, Basel Switzerland) and plated using one 
petri dish per PCR product. One white colony from every plate was selected and 
incubated in 6-8 ml LB-medium (prepared by laboratory technicians) overnight 
followed by plasmid extraction (QIAprep Spin Miniprep Kit). The plasmids were sent 
in for sequencing using the primers M13 and M13r. The returned sequences were 
edited, assembled and analyzed with Geneious software (version 8.1, Biomatters 
Limited). All sequences were compared to the nucleotide collection and the 
Reference Sequence (RefSeq) collection of Felis catus genome at NCBI and at 
Ensemble using Basic Local Alignment Search Tool (BLAST; 
https://blast.ncbi.nlm.nih.gov/Blast.cgi). The detection of exogenous LTR sequences 
adjacent to feline genome sequences verified proviral integration events. To identify 
possible CIS the genes near insertion sites were compared to insertion sites of the 
mouse on the Retrovirus and Transposon tagged Cancer Gene Database (RTCGD) 
(National Cancer Institute at Frederick, 2004, Akagi et al., 2004) and to two human 
databases one was Tumor Associated Gene (TAG) (NCKU Bioinformatics Center, 
2013, Chen et al., 2013) and the other was the catalogue of somatic mutations in 
cancer (COSMIC) (Wellcome Sanger Institute, 2004, Forbes et al., 2017). 
 
4.5 Sequencing of the plasmid pFGA-5 (FeLV-A/Glasgow-1) 
Since FeLV-A/Glasgow-1 had only been previously partially sequenced the plasmid 
pFGA-5 (Stewart et al., 1986) (kindly provided by Professor B. Willett of the 
University of Glasgow, GB) containing the whole genome of FeLV-A/Glasgow-1 
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(12,709 bp) was entirely sequenced (GenBank: KP728112.1), thus allowing better 
sequence comparison of FeLV-A/Glasgow-1 with its progenies and recombinant 
constructs. For this purpose, the primers described in Table 1 were used. All primers 
were commercially synthesized (Microsynth, Balgach, Switzerland).  
 
Table 1: PCR primers used for amplification and sequencing of FeLV-A/Glasgow-1 
Name	 Sequence	5'-3'		 Length	
(bp)	
Reference	
Glasgow-1/	29F	 CAGCTACTGCAGTGGTGTCATTTC	 24	 This	study	
Glasgow-1/	29R	 GAAATGACACCACTGCAGTAGCTG	 24	 This	study	
Glasgow-1/	476R	 GAGCCCCCAAATGAAAGAC	 19	 This	study	
Glasgow-1/	770R	 CCCTCGTCTCCGATCAACAC	 20	 This	study	
Glasgow-1/	898F	 GAAACCGTCATGGGCCAAAC	 20	 This	study	
Glasgow-1/	1346R	 GAGGAAGGATCAGGCGGTAAC	 21	 This	study	
Glasgow-1/	2400F	 CTCCACTCTCCTCAACTTAG	 20	 This	study	
Glasgow-1/	2560R	 GGTCACTGAGAGGTCCATCTG	 21	 This	study	
Glasgow-1/	3249F	 TTTCTGCCTGCGACTACAC	 19	 This	study	
Glasgow-1/	4066F	 CTAGGACAGCCGCTAACTATC	 21	 This	study	
Glasgow-1/	4785F	 AACCGTCTTACCCACTGAAC	 20	 This	study	
Glasgow-1/	5059R	 GGAGGTGTAAGTCTCTGTTAGG	 22	 This	study	
Glasgow-1/	5436R	 GGGTCGGTATGCACAATG	 18	 This	study	
Glasgow-1/	5617F	 CCTATGGCTCACTTCTTTGATACTGAT
ATCTCTA	
34	 (Meli	et	al.,	2009)		
Glasgow-1/	5847F	 ACATATCGTCCTCCTGACGAC	 21	 (Chandhasin	 et	 al.,	
2005a)	
Glasgow-1/	6058R	 CCCACCAGAAACGCTAAG	 18	 This	study	
Glasgow-1/	6382F	 TGGGGCCAAAGGGAACACAT	 20	 (Meli	et	al.,	2009)	
Glasgow-1/	7266F	 TACCATCAACCCGAATATGTGTACACA	 27	 (Meli	et	al.,	2009)	
Glasgow-1/	7691F	 CGGCAACAACTGTTTGACTCC	 21	 This	study	
Glasgow-1/	7691R	 GGAGTCAAACAGTTGTTGCCG	 21	 This	study	
pFGA1_catF	 GATCATCTCAGCCAGCATGATAAAC	 25	 This	study	
Glasgow-1/	10123R	 TGATAGACGCAGCCAAGCAA	 20	 This	study	
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4.6 Construction of recombinant FeLV 261 proviruses 
Recombinant FeLV-A/261 proviruses were constructed by substituting the LTR or the 
env gene of FeLV-A/261 from the horizontally transmissible prototype isolate, FeLV-
A/Glasgow-1 (see Figure 2) according to the method described by Chandhasin et al 
(Chandhasin et al., 2005a, Athas et al., 1995b). PCR was performed to amplify 
different LTR-sequences out of DNA from the sternal lymph node tissue of the cat 
#261 with the primers FeLV-LTR-F1 (5’-CAATACGATCCGGACCGACC-3’) and 
FeLV-LTR-R1-SalI (5’-GTATCCAACGGTCGACTGAAAGACCCCCGAACTAGGTC-
3’) including an additional SalI site. The PCR product was then separated on a 1% 
agarose-gel. Bands of the expected size (~572 bp) were cut out and DNA was 
purified by QIAquick Gel Extraction Kit (Qiagen). After pCR®4-TOPO® TA cloning, 
colonies were sent for sequencing (Microsynth) with the primers M13 and M13r. Four 
different LTR-variants were obtained; two among them had been described earlier as 
pKH11.1 [GenBank: FJ613291] and pKH12.1 [GenBank: FJ613295] (Helfer-
Hungerbuehler et al., 2010). The new variants were termed Cat261-LTR1 and 
Cat261-LTR3 [GenBank: KU962189 and KU962190], respectively. The clones 
containing the different LTR-variants were digested with CpoI (RsrII) and SalI 
resulting in a fragment of approximately 572 bp. The plasmid containing FeLV-
A/Glasgow-1 (pFGA-5) (see Figure 3) was digested with CpoI and SalI as well 
resulting in a backbone fragment of 11,943 bp lacking the LTR. A ligation step was 
performed using T4 DNA Ligase (Thermo Scientific, Reinach, Switzerland) overnight 
at 16°C ligating the FeLV-A/Glasgow-1 backbone with one of the four different LTR 
variants (FeLV-A/261L11; FeLV-A/261L12; FeLV-A/261L1; FeLV-A/261L3). 
Correctness of sequence ligations was verified at the beginning of the experiments 
by sequencing (Microsynth). All FeLV-A/Glasgow-1 LTR progenies were also re-
sequenced (Microsynth) at the end of the replication study. No mutational changes 
occurred during the time the progenies were in cell culture.  
The variant env SP261-III (EU359305; obtained from a spleen sample of the cat 
#261) was cut out from an already existing plasmid, termed p25 (kindly provided by 
Valentino Cattori, Clinical Laboratory; vector: pCR®II-TOPO®, Invitrogen, Paisley UK, 
insert: S261-III), with the restriction enzymes CpoI and XhoI, resulting in a 2,080 bp 
fragment. Digestion of FeLV-A/Glasgow-1 with CpoI and XhoI resulted in a 10,589 bp 
long backbone. To obtain a virus composed of FeLV-A/Glasgow-1 backbone and 
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SP261-III env the same ligation step as described above was applied. The obtained 
ligation product was termed FeLV-A/261env. 
 
 
Figure 2: Diagram of recombinant FeLV proviruses constructed by replacing the 
envelope gene or LTR of FeLV-A/Glasgow-1 with envelope or LTRs of the variants 
detected during FeLV infection of cat #261 (gray shaded area). * The four different 
LTR variants were L1, L3, L11, L12. Adapted from (Chandhasin et al., 2005a) 
FeLV-A/Glasgow-1 
FeLV-A/261env 
FeLV-A/261L* 
*4 different LTR variants  
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Figure 3: Map of the plasmid pFGA-5 (FeLV-A/Glasgow-1) with selected restriction 
sites created with SnapGene®. The restriction enzymes used in this study are in bold 
(SalI, CpoI and XohI). 
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4.7 Cell culture 
All cells lines used in this study were tested for absence of FeLV infection by p27 
FeLV ELISA from the cell culture supernatant (Lutz et al., 1983) and using ExoFeLV 
U3 real-time PCR and DNA extracted from cell pellets of the cultures (see 4.8.2). 
 
4.7.1 Preparation of virus stocks 
In order to prepare infectious viral stocks, feline embryonic fibroblasts (FEA) (Jarrett 
et al., 1973) were transfected with plasmid DNA containing the recombinant or the 
prototype FeLV-A/Glasgow-1 viruses. Transfection was performed using an 
optimized Lipofectamine 2000 protocol (Life Technologies™; Carlsbad, California) 
when cells reached a confluency of approximately 70%. Lipofectamine in Opti-Mem-
Medium (Gibco by Life Technologies, Stockholm, Sweden 11058-021) was mixed 
with diluted plasmid DNA, added to cells seeded on a 24-well plate and incubated for 
4 hours. After a washing step with Roswell Park Memorial Institute medium (RPMI; 
Gibco, Life Technologies,) the medium was changed to RPMI containing 10% fetal 
calf serum (FCS). Transfection conditions were set at a final Lipofectamine 
concentration of 1.5 µL per ml and a DNA concentration of 500 ng per ml. By p27 
FeLV antigen ELISA from culture supernatant collected at day 5 after transfection, a 
productive infection was confirmed and the cells were maintained for four weeks to 
collect supernatant. Supernatant was aliquoted and stored at -80°C. The Tissue 
Culture Infection Dose 50 (TCID50) was determined by titration as described by the 
Spearman & Kärber algorithm (Hierholzer and Killington, 1996). The titration was 
performed on 12-well plates containing 80% confluent FEA cells in 1 ml RPMI. One 
aliquot of stock solution of viral supernatant was diluted on ice in a tenfold serial 
dilution (undiluted, 10-1, 10-2, 10-3, 10-4 and 10-5). An aliquot of the virus stock and 
each dilution was stored at -80°C. The FEA cells were inoculated with 1 ml of every 
dilution in triplicates and incubated at 37°C, 5% CO2 for two hours. After the 
incubation the inocula were removed and 1.5 ml RPMI complete was added to each 
well. Plates were maintained for one week at 37°C, 5% CO2. At day 4 and day 7 0.5 
ml supernatant from each well were collected and stored a -80°C. A p27 antigen 
ELISA was performed with all stored aliquots and the TCID50 was then calculated.  
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4.7.2 Virus replication kinetics 
FEA cells were seeded at a density of 20,000 cells per well on a 24-well plate and 
were transfected with the recombinant proviruses and the original challenge virus 
FeLV-A/Glasgow-1 as described above in quadruplicates. Supernatant was collected 
at days 3, 5, 7, 10, 12, 14, 17, 21 and 24. Cells were passaged every seventh day. A 
FeLV p27 antigen ELISA was directly performed from the supernatant collected. 
Quantitative PCR was performed using cDNA from viral RNA extracted from the 
supernatants (for details see 4.2, 4.3 and 4.8.3). At the end of the experiment the 
infected FEA cells were harvested, the genomic DNA extracted and the sequences of 
the recombinants were obtained (Microsynth) to ensure conformity with the 
inoculated strains. 
 
4.7.3 Host range comparing FeLV-A/261env to FeLV-A/Glasgow-1 
The following adherent cell lines were used in this study: feline embryonic fibroblasts 
(FEA) (Jarrett et al., 1973), Crandell-Rees feline kidney cells (CRFK) (ATCC CCL-94), 
Madin-Darby canine kidney cells (MDCK) (ATCC CCL-34), Mus dunni tail fibroblasts 
(MDTF) (ATCC CRL-2017), Guinea pig fibroblasts 104C1 (ATCC CRL-1405) and 
porcine ST-IOWA (ATCC CRL-1746). Cells were maintained in RPMI 1640 medium 
supplemented with 10% FCS, 1% Gibco® Antibiotic-Antimycotic containing 10,000 
units/ml of penicillin, 10,000 µg/ml of streptomycin, 25 µg/ml of Fungizone® 
Antimycotic and 2 mM L-glutamine (Gibco, Life Technologies, 25030-081). Human 
embryonic kidney cells (HEK293) (ATCC CRL-1573) and human HeLa cells (ATCC 
CCL-2) were as well maintained in RPMI 1640 medium supplemented with 5% FCS, 
antibiotic-antimycotic and L-glutamine. The cells were cultured in an incubator at 
37°C infused with 5% CO2. 
Cells of every cell-line were seeded at a density of 20,000 cells per well on a 24-well 
plate. Four wells each were infected at a multiplicity of infection (MOI) of 0.001 with 
FeLV-A/Glasgow-1 or FeLV-A/261env supernatant. Two wells contained uninfected 
cells as negative control. Infection time was four hours, followed by a washing step 
with RPMI. Cells were passaged, when reaching a confluency of 90% and 
maintained up to thirteen days. FeLV p27 ELISA was performed at days 3, 5, 8, 10 
and 13 to detect a productive infection.  
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4.8 PCR assays 
4.8.1 Detection of FeLV subgroups by conventional PCR 
FeLV-subgroups were investigated by conventional PCR using the FeLV-A specific 
primers RB59 and RB17, the FeLV-B specific primers RB53 and RB17 and the 
FeLV-C specific primers RB58 and RB47 as described (Mathes et al., 1994, Sheets 
et al., 1993). (Table 2) 
 
Table 2: Primer for FeLV subgroup PCR 
FeLV-subgroups Primer Name Sequence 5’-3’ Reference 
FeLV-A  RB59  CAATGTAAAACACGGGGCAC 
(Mathes et al., 
1994, Sheets et al., 
1993) 
FeLV-A / FeLV-B RB17 TAGTGATATTGGTTCTCTTCG 
FeLV-B RB53 ACAACGGGAGCTAGTG 
FeLV-C RB58 AGATCTTGGGCACGTTATTCC 
 RB47 TTGTGAAATGGCATTGCTGC 
 
4.8.2 Env TaqMan® and S261-III env real-time PCR assays 
GenomeWalker libraries were tested with the env TaqMan® real-time PCR which is 
specific for FeLV-A/Glasgow-1 and the SP261-III env PCR that is specific for the 
Variant S261-III (Helfer-Hungerbuehler et al., 2010, Flynn et al., 2002) to determine 
the ratio of S261-III to FeLV-A/Glasgow-1. From every library one sample was tested 
in both PCRs. The mean for the env TaqMan® real-time PCR was 1.5 (range 0 – 5.4) 
copies per reaction while the mean of the S261-III env PCR was 52,000 (range 
49,300 – 57,100) copies per reaction, which is roughly 1 copy of FeLV-A/Glasgow-1 
to 35,000 copies of variant S261-III. For details to the used PCR systems see Table 
3.  
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Table 3: Primer and Probes for FeLV real-time PCR assays  
System Name Sequence 5’-3’ Reference 
Env specific 
Glasgow-1 
FeLVenvf GCCCCAAACGAATGAAAGC 
(Flynn et al., 
2002) 
FeLVenvr AATCCGTTTGGGACCCATG 
FeLVenvp CCCAAGGTCTGTTGCCCCCACC1 
SP261-III env 
PCR 
 
261-gen-F-
CORRECT 
GATCCGGACCGACCATAATTAA 
(Helfer-
Hungerbuehler 
et al., 2010)  
Primer 261gen-IIIR ACACCACTGCAGTAGCTGGCTAA 
261genP TGTATGATTCCATTTAGTCCC1 
1 5’ FAM/ 3’ TAMRA 
 
4.8.3 FeLV gag TaqMan® real-time PCR assay 
A new real-time PCR assay was designed in the highly conserved gag region for 
better assessment and comparison of the different env and LTR variants. Probe and 
primer sequences were designed using Geneious software (version 8.1, Biomatters 
Limited). Primer and probe sequences were selected within the gag region of FeLV-
A/Glasgow-1, to ensure that all recombinant provirus variants were detectable, but 
not endogenous FeLV sequences; this was confirmed using genomic TNA from 30 
FeLV-negative SPF cats (data not shown). PCR amplification using the forward 
primer G1-1515F (5’-CAACAACCGACCCCAGTATT-3’) in a concentration of 0.3 µM 
and the reverse primer G1-1611R (5’-AGTTAGGGCCACTGGATCTT-3’) in a 
concentration of 0.9 µM resulted in a PCR product of 97 bp. The probe (5’-
CAGCTTCAGACTTGTATAACTGGAAGTCGCA-3’) was labelled at the 5’-end with 
the fluorescent reporter dye FAM and at the 3’-end with the dark quencher dye BHQ-
1. DNA was amplified and quantified in an ABI Prism 7500Fast sequence detection 
system using TaqMan® Fast Universal PCR Master Mix (Applied Biosystems). 
Optimal PCR conditions are as follows: One cycle of 95°C for two min, 45 cycles of 
94°C for 3 s followed by 60°C for 30 s.  
For the production of a standard for absolute quantification a sequence in the FeLV 
gag region with the length of 515 bp was cloned into pUC57-Kan (GeneScript USA 
Inc., Piscataway, New Jersey) using EcoRV as cloning site. The plasmid was 
digested with HindIII (Thermo Scientific). Ten-fold serial dilutions of the standard with 
nuclease-free water containing 30 µg/ml carrier salmon sperm DNA (Invitrogen, 
Basel, Switzerland) was made starting from 108 copies per 5 µL to 10-1 copies per 5 
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µL. The real-time TaqMan® PCR system was optimized as described in (Kessler et 
al., 2009) using cDNA and a 3 × 3 primer matrix with 50, 300 and 900 nM end 
concentrations. Each of the nine conditions was run in quadruplicate under the 
conditions described above. Moreover, using the best primer concentration, five 
different probe end concentrations (50, 100, 150, 200 and 250 nM) were tested for 
optimal performance. The sensitivity of the gag real-time PCR assay was determined 
by an endpoint dilution experiment: Triplicates of standard dilutions from 108 to 102 
copies per reaction and ten replicates of dilutions from 101 to 10-1 copies per reaction 
were tested. The sensitivity of the assay is given by the dilution in which at least 
seven of 10 replicates are still positive (Lockey et al., 1998).  
The intra-run precision of the TaqMan® real-time PCR assay was determined using 
tenfold serial dilutions of the plasmid standard. Between-run precision was assed 
using the 105 dilution in five separate experiments. For all measurements, mean 
value, standard deviation and coefficients of variation (CV) were calculated for the 
threshold cycle (CT). 
 
4.9 Statistics 
Statistical analyses were performed with GraphPad Prism for Windows (version 3.0, 
GraphPad software, San Diego, CA). Differences among three or more groups were 
analyzed by the non-parametric Kruskal-Wallis one-way ANOVA by Ranks (pKW) for 
unpaired samples and Dunn’s posttest. If only two groups were compared, the 
Mann–Whitney U-test (pMWU) was used. Differences were considered significant if p < 
0.05.  
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5 Results 
5.1 Evaluation of the newly developed gag TaqMan® real-time PCR 
assay 
A gag TaqMan® real-time PCR was developed in a conserved area to detect all 
FeLV variants. Primer and probe concentrations for the newly designed gag 
TaqMan® real-time PCR assay were optimized using cDNA of an experimentally 
FeLV-A/Glasgow-1 infected cat and a primer matrix and different probe 
concentrations. The maximal sensitivity (minimal Ct values) and very high 
fluorescence was reached using the concentrations listed in Table 4. 
 
Table 4: Optimal final concentration of primers and probe for the gag TaqMan® real-
time PCR 
Forward Primer (nM) Reverse Primer (nM) Probe (nM) 
300 900 250 
 
Using these concentrations, the amplification efficiency of the new gag TaqMan® 
real-time PCR assay was >96%. The lower detection limit of the assay was equal to 
one copy of target standard plasmid per reaction in an endpoint dilution experiment 
(10 out of 10 reactions with a single copy/reaction were positive). We observed 
linearity of the assay over a 108-fold range. The coefficient of variation for the intra-
run precision CVintra was 0.53% ± 0.32 and for the inter-run precision CVinter 0.65% ± 
0.57.   
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5.2 Proviral integration sites of FeLV-A/Glasgow-1 progeny viruses 
GenomeWalker libraries were tested with the exo FeLV U3 (Tandon et al., 2005) and 
env TaqMan® real-time PCR (Helfer-Hungerbuehler et al., 2010, Flynn et al., 2002) 
to determine the variant SP261-III to FeLV-A/Glasgow-1 ratio, which was up to 
35,000 copies of the variant SP261-III versus one copy of FeLV-A/Glasgow-1. Using 
genome walking we screened proviral integration sites in tumor tissues of animals 
#261 (sternal lymph node, LN) and #67 (tumor tissue of the thymic lymphoma, T). 
The sequences were blasted and mapped on the cat reference genome; 12 out of 33 
blasted sequences could be placed on the cat genome; the remaining 21 sequences 
were vector sequences. Out of the 12 feline sequences, eight derived from cat #261 
and four sequences were from cat #67. Sequences from the cat #261 were mapped 
on five different chromosomes and those from cat #67 on two different chromosomes, 
including two different locations on chromosome D4 (Table 5). In four cases two 
independent inserts in the same region could be found. However, none of the 
insertion sites were identical in cats #261 and #67. 
The integration sites found in cats #261 and #67 were compared to previously 
described common insertion sites (CIS) in the cat (myc, pim-1, flvi-1, flvi-2 or bmi-1, 
flit-1, fit-1) (Fujino et al., 2009, Tsatsanis et al., 1994, Levy et al., 1993). None of the 
herein found insertions sites were identical with previously described CIS in cats and 
the novel insertion sites were all located on different chromosomes then the 
previously described CIS in cats (which were on B2, B4 and F2).  
While most of the integrations occurred in regions between host genes, two inserts 
were found within two genes in cat #261. These two genes were the Pseudouridylate 
Synthase 10 (PUS10; in intron) and the Sorting Nexin 25 (SNX25; in intron and exon). 
For cat #261 other integrations occurred between MAP3K12 binding inhibitory 
protein 1 (MBIP) and thyroid transcription factor 1 (TTF1 or NKX2-1), between the 
genes dopamine receptor D2 (DRD2) and transmembrane protease, serine 5 
(TMPRSS5) and between the Toll-like receptor 5 (TLR5) and the sushi domain 
containing 4 (SUSD4) genes. For cat #67 the integrations occurred between growth 
factor independent 1B transcription repressor (GFI1B) and general transcription 
factor IIIC, polypeptide 5 (GTF3C5), between the genes family with sequence 
similarity 102, member A (FAM102A) and nuclear apoptosis inducing factor 1 (NAIF1) 
and between the NK2 Homeobox 2 (NKX2-2) and the paired box 1 (PAX1) genes.  
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Table 5: Listed are the integration sites found in cat #261 and cat #67. The 5’ and 3’ genes, their functions (selected) and the 
distance to the proviral integration site are listed according to the feline genome. Potentially tumor associated functions in bold.  
Cat 
(Tissue) 
Cat 
chrom.  
Gene 5' Functions Distance* No. of 
inserts 
Distance Gene 3' Functions Hum. 
chrom.  
261 (LN) A3 PUS10 Apoptosis In intron 3 2 In intron 3 PUS10  2p16.1 
 B1 SNX25 Function in cellular 
trafficking 
In intron 6 
In exon 7 
2 In intron 6 
In exon 7 
SNX25  4q35.1 
 B3 MBIP Protein kinase inhibitor, 
chromatin organization 
79.0 kb 2 87.0 kb NKX2-1 Tumor associated, 
oncogene or tumor 
suppressor 
14.q13.3 
 D1 DRD2 D2 subtype of the dopamine 
receptor, upregulated in 
some cancers 
58.0 kb 1 117.0 kb TMPRSS5 Protease of the 
serine protease 
family 
11q23.2 
 F1 TLR5 Pathogen recognition, NF-
kB mobilization 
18.0 kb 1 10.0 kb SUSD4 Complement inhibitor 1q41 
67 (T) D4 GFI1B Homolog to GFI1 = 
integration site of MLV-
induced lymphoma in rats 
8.0 kb 1 10.0 kb GTF3C5 RNA polymerase III-
mediated 
transcription 
9q34.13 
 D4 FAM102A Estrogen action and bone 
homeostasis 
2.3 kb 2 48.0 kb NAIF1 Apoptosis, down-
regulated in cancer 
9q34.11 
 A3 NKX2-2 Target gene and tumor 
marker in Ewing’s sarcoma 
29.0 kb 1 133.0 kb PAX1 Tumor suppressor, 
silenced in cancer 
20p11.22 
LN: Lymphoma sternal lymph node. T: Thymic lymphoma; for gene abbreviations see text. MLV: Murine leukemia virus. * If the insertion site 
was within the gene, the intron or exon number is listed. 
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During the application of the GenomeWalker kit questions were raised whether the 
provided restriction sites were viable using in the cat genome and whether some 
integration sites would be missed if restriction sites were absent from genes or too far 
from each other. To exclude a bias from the chosen restriction enzymes, the 
restriction sites present in the two genes found in cat #261 (PUS10 and SNX25) were 
examined with the Geneious program and compared to the restriction sites of three 
CIS (myc, pim-1, bmi-1) described in the cat (see Table 6). A maximum deviation of 
2.5-fold was seen in the restriction analysis of the enzyme DraI between PUS10 and 
myc. The total count of restriction sites over the 500 kb length of each gene is similar, 
as one could theoretically find a restriction site every 470 bp (for PUS10 with the 
maximal count of sites) or 640 bp (for myc with the minimal count of sites), 
respectively. The numbers show that for example the detection of a supposed 
integration near myc would have been possible with the chosen restriction sites.  
 
Table 6: Restriction enzyme digestion of 500 kb surrounding the genes (250 kb 3’ 
and 5’ of the gene of interest) found in cat #261 (PUS10, SNX25) compared with 
three different CIS genes (myc, pim-1, bmi-1) with the restriction enzymes used in 
the GenomeWalker 2.0 kit.  
Gene DraI EcoRV PvuII StuI Total 
PUS10 859 64 152 82 1157 
SNX25 795 83 185 88 1151 
myc 312 49 262 166 793 
pim-1 499 53 220 149 921 
bmi-1 (Flvi-2) 716 50 161 115 1042 
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5.3 Characterization of the recombinant provirus constructs 
5.3.1 Sequence comparison of the env variants 
Three heavily mutated FeLV-A env variants were identified previously (Helfer-
Hungerbuehler et al., 2010). For the current study the most abundant env variant, 
SP261-III [GeneBank: EU359305], was used and cloned into the backbone of FeLV-
A/Glasgow-1 and further characterized in an in vitro experiment (see chapter 5.4 and 
5.5). In Figure 4 an alignment of the amino acid sequences of the FeLV envelope of 
FeLV-A/Glasgow-1 and SP261III is shown. The amino acid identity was 91%. 
Sequence divergences between these two envs were pronounced at the regions 
variable region A (VRA), variable region B (VRB), variable region C (VRC), proline-
rich region (PRR) and the C2-loop.  
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10 20 30 40 50 60 70
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 1 MESPTHPKPSKDKTLSWNLAFLVGILFTIDIGMANPSPHQIYNVTWVITNVQTNTQANATSMLGTLTDAY 70
261-env 1 ...S............GY......F............................GA...T........... 70
80 90 100 110 120 130 140
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 71 PTLHVDLCDLVGDTWEPIVLNPTNVKHGARYSSSKYGCKTTDRKKQQQTYPFYVCPGHAPSLGPKGTHCG 140
261-env 71 ......................HST....L.YTP......PE.R....A...........LM.....Y.. 140
150 160 170 180 190 200 210
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 141 GAQDGFCAAWGCETTGEAWWKPTSSWDYITVKRGSSQDNSCE---GKCNPLVLQFTQKGRQASWDGPKMW 207
261-env 141 .....Y..........D..............T........D.ACNT....................R.A. 210
220 230 240 250 260 270 280
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 208 GLRLYRTGYDPIALFTVSRQVSTITPPQAMGPNLVLPDQKPPSRQSQTGSKVATQRPQTNESAPRSVAPT 277
261-env 211 .....................................N.....---.................L...T.P 277
290 300 310 320 330 340 350
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 278 TMGPKRIGTGDRLINLVQGTYLALNATDPNKTKDCWLCLVSRPPYYEGIAILGNYSNQTNPPPSCLSTPQ 347
261-env 278 .IN..W..........................................V..........S.......... 347
360 370 380 390 400 410 420
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 348 HKLTISEVSGQGMCIGTVPKTHQALCNKTQQGHTGAHYLAAPNGTYWACNTGLTPCISMAVLNWTSDFCV 417
261-env 348 ......................R.........YN.TR..V.............................. 417
430 440 450 460 470 480 490
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 418 LIELWPRVTYHQPEYVYTHFAKAVRFRREPISLTVALMLGGLTVGGIAAGVGTGTKALLETAQFRQLQMA 487
261-env 418 ............S..M.......................................T.............. 487
500 510 520 530 540 550 560
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 488 MHTDIQALEESISALEKSLTSLSEVVLQNRRGLDILFLQEGGLCAALKEECCFYADHTGLVRDNMAKLRE 557
261-env 488 ...............................................................S...... 557
570 580 590 600 610 620 630
....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Glasgow-1 558 RLKQRQQLFDSQQGWFEGWFNKSPWFTTLISSIMGPLLILLLILLFGPCILNRLVQFVKDRISVVQALIL 627
261-env 558 ..R........ER....................T.................................... 627
640 650 660
....|....|....|....|....|....|....|.
Glasgow-1 628 TQQYQQIKQYDPDRP*FPIKCMIPFSPQKKGGMKDP 663
261-env 628 .......R.......*--.................. 661
Start of SU 
Start of U3 
Start of TM 
VRA VRC 
VRB 
PRR 
C2 loop 
End of env 
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Figure 4: Amino acid alignment of FeLV env sequences. Amino acid alignment of the 
env coding region from FeLV-A/Glasgow-1 [GeneBank: M12500] and the variant 
SP261-III (261env) [GeneBank: EU359305]. The start of the SU region, the 
transmembrane domain (TM), the variable regions VRA, VRB and VRC, the PRR 
and the C2 disulfide-bonded loop (S-S) are indicated (according to (Rey et al., 
2008b)). Dots represent identical residues, and dashes represent spaces, which 
were introduced for proper alignment. Adapted from (Rey et al., 2008b).  
End of env 
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5.3.2 Sequence comparison of the LTR variants 
Previously nine different LTR variants had been described (Helfer-Hungerbuehler et 
al., 2010). Out of these nine variants two were available for this study (261L11 and 
261L12 [GenBank: FJ613291 and FJ613295]). In addition, two new variants were 
found and included into the study (261L1 and 261L3 [GenBank: KU962189 and 
KU962190]). Four LTR-recombinants were constructed. An overall sequence 
conservation of 96-98% was seen when the full-length progeny LTR sequences were 
compared to FeLV-A/Glasgow-1 (see Table 7). 
 
Table 7: Genetic distances between LTRs of FeLV-A/Glasgow-1 and of FeLV-A/261 
recombinants 
  Glasgow-1 261L1 261L3 261L11 261L12 
Glasgow-1 
 
    
261L1 96.48%     
261L3 97.10% 97.31% 
 
  
261L11 98.34% 97.31% 97.52% 
  
261L12 96.49% 94.22% 96.90% 96.07% 
 
 
The alignment of the four different FeLV-A/261 LTR variants and FeLV-A/Glasgow-1 
showed 33 locations of point mutations, insertions or deletions (see Figure 5). 
Changes were found in the simian virus 40 core enhancer (CORE), the Leukemia 
virus factor b (LVb), the nuclear factor 1 (NF1), the glucocorticoid response element 
(GRE) and the FeLV-specific binding motif (FLV-1). 261L1 and 261L12 had changes 
in the LVb, the CORE, the NF1 and the GRE sites. 261L3 showed changes in the 
NF1 and the 261L11 had changes in the NF1. Influence of these mutations on 
replication efficiency and host range was investigated in further studies (see 5.4 and 
5.5).   
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Figure 5: Comparison of nucleotide sequences of the FeLV U3 region. Nucleotide 
comparison of the U3 region from four LTR variants retrieved from cat #261 and 
FeLV-A/Glasgow-1 [GenBank: M12500]. Nuclear protein-binding sites (LVb, CORE, 
NF1; GRE and FLV-1) and their corresponding nucleotide sequences are marked in 
the reference strain FeLV-A/Glasgow-1 (according to (Hisasue et al., 2009)). Dots 
indicate identity with FeLV-A/Glasgow-1 sequence. Dashes indicate gaps. The stop 
codon of env in FeLV-A/Glasgow-1 is indicated with a solid left right arrow (TGA) the 
one of the variants with a dashed left right arrow (TAA). Nucleotides differing from the 
originally inoculated strain are indicated. Numbers at the top of the sequence indicate 
nucleotide positions relative to the presumptive RNA cap site in the FeLV-
A/Glasgow-1 LTR (Stewart et al., 1986).  
Stop	of	env	
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5.4 Replication efficiency of FeLV-A/Glasgow-1 and progeny viruses 
In vitro experiments were performed to determine whether the mutational changes in 
the FeLV-A/261 env and LTR recombinants influenced the rate of virus replication. 
Plasmid DNAs encoding infectious viruses of the recombinants and the original 
challenge strain FeLV-A/Glasgow-1 (pFGA-5) were transfected into FEA cells. Virus 
replication was then quantified by measuring FeLV p27 ELISA antigen levels and 
viral RNA using quantitative real-time gag PCR from cell culture supernatants at 
regular time intervals (Figure 6A-J).  
Significant differences in replication efficiency were found between the original 
challenge strain FeLV-A/Glasgow-1 and the recombinants containing env and LTR of 
the progeny viruses. Remarkably, the progeny env and LTR recombinants showed 
largely lower replication efficiency than the prototype virus FeLV-A/Glasgow-1 
(Figure 6 and Figure 7). The differences were more pronounced, when p27 antigen 
was measured in the cell culture supernatant then when viral RNA was quantified.  
A constant significant difference over the whole 24-days observation period was 
found for FeLV-A/261env starting at day 3 after transfection using p27 antigen 
detection and at day 5 after transfection using viral RNA as read-out in the cell 
culture supernatant (Figure 6E and J and Figure 7, pMWU < 0.05). Similarly, a 
constantly lower replication efficiency was found for variants 261L1 and 261L11 in 
the p27 antigen ELISA (Figure 6F and H; pMWU = 0.0286). Moreover, variant 261L12 
was also constantly lower when measuring viral RNA loads (Figure 6D; pMWU = 
0.0286) and with the exceptions of days 5 and 10 in p27 antigen loads (Figure 6I; 
pMWU = 0.0286). In contrast, the variant 261L3 only had a poor replication rate during 
the initial phase of virus replication (10 days for viral RNA and 17 days for p27 
antigen levels) but then reached similar viral RNA levels like the prototype virus 
FeLV-A/Glasgow-1 (Figure 6B and G).  
In order to confirm that this change over time in replication efficiency of all variants 
was not due to mutational changes in the LTR acquired during the in vitro experiment, 
the variants were re-sequenced at the end of the replication study. No changes in the 
LTRs were observed. 
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Figure 6: Results of FeLV gag PCR (A-E) and p27 ELISA (F-J) in a replication 
efficiency experiment comparing each progeny virus variant against FeLV-
A/Glasgow-1 during the time course of 24 days. Each data point represents the mean 
value and its standard deviation of four replicates. In A and F data of the env-variant 
compared to FeLV-A/Glasgow-1 are shown. B-E and G-J contain data of the LTR-
variants compared to FeLV-A/Glasgow-1. Differences between the variants against 
FeLV-A/Glasgow-1 (pFGA-5) were tested for significances using the Mann-Whitney 
U-test: * = p < 0.05.  
	
	
  
Figure 7: Summary of the results of FeLV gag PCR (left) and p27 ELISA (right) in a 
replication efficiency experiment comparing each progeny virus variant against FeLV-
A/Glasgow-1 during the time course of 24 days. Each data point represents the mean 
value of four replicates.  
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5.5 Titration and host range of FeLV-A/Glasgow-1 and progeny 
viruses 
5.5.1 Results of the titration experiment 
The titration experiment was carried out to determine infectivity (multiplicity of 
infection or MOI) of the viruses FeLV-A/Glasgow-1 (Table 8) and FeLV-A/261env 
(see Table 9) in FEA cells. The results from these experiments were used to 
determine dilutions with similar infectivity for comparing both virus strains in the later 
host range experiment. The MOI, M, is given by the equitation ! = (0.7 × ! × !)/(!" × !),	where	N is the TCID50 calculated by the Spearman & Kärber algorithm, V is 
the volume of virus stock per Well, Df is the dilution factor and X is the amount of 
cells per well. In Table 10 the values used in the calculations and their results for 
FeLV-A/Glasgow-1 and FeLV-A/261env are shown.	
For the later host range experiment we used the undiluted stock solution of FeLV-
A/Glasgow-1 and a tenfold dilution thereof to match the virus concentration of the 
undiluted stock solution of FeLV-A/261env.  
	
Table 8: Results of FeLV p27 ELISA in percentage at day 6 after infection in the 
titration experiment testing FeLV-A/Glasgow-1 on FEA cells. Every result > 4% was 
rated positive and indicated in bold.  
Stock 10-1 10-2 10-3 Negative 
control 
36.2 13.3 6.4 0.0 2.4 
26.0 11.1 3.9 0.8 3.2 
29.0 11.9 1.1 0.3 2.4 
27.7 14.2 4.8 0.8 3.0 
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Table 9: Results of FeLV p27 ELISA in percentage at day 8 after infection in the 
titration experiment testing FeLV-A/261env on FEA cells. Every result > 4% was 
rated positive and indicated in bold. 
Stock 10-1 10-2 10-3 Negative 
control 
11.2 1.3 0.0 0.0 0.2 
15.5 3.8 0.0 0.5 0.0 
13.5 2.7 0.0 0.1 0.0 
9.9 0.0 0.2 0.0 0.0 
	
Table 10: Listed are the values used in the equitation ! = (0.7 × ! × !)/(!" × !) to 
calculate the MOI for FeLV-A/Glasgow-1 and FeLV-A/261env.  
Variable Meaning FeLV-A/Glasgow-1 FeLV-A/261env 
N TCID50/ml  100 3.16 
V Volume / Well  1 ml 1 ml 
X Cells / Well  20,000 20,000 
Df Dilution factor  1 1 
M MOI 0.0035 0.00011 
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5.5.2 Results of the host range experiment 
The host range is determined by the receptor usage that is specific for each FeLV 
subgroup. Mutational changes in regions that are crucial for receptor interactions and 
viral entry might change the host range.  
The two feline cell lines, FEA and CRFK, were successfully infected not only by 
FeLV-A/Glasgow-1 but also by FeLV-A/261env (Table 11). HeLa, M. dunni, ST-
IOWA and 104C1 were not susceptible to an infection with either FeLV-A/Glasgow-1 
or FeLV-A/261env. In contrast canine MDCK cells could only be infected with FeLV-
A/Glasgow-1 but not with FeLV-A/261env. While HEK293 cells should be susceptible 
to an infection with FeLV-A (Nakata et al., 2003) only the higher virus concentration 
(MOI 0.0035) of FeLV-A/Glasgow-1 led to an infection. No infection of HEK293 cells 
was observed by FeLV-A/Glasgow-1 at a lower MOI of 0.00035 and by FeLV-
A/261env at the MOI of 0.00011.  
 
Table 11: Host Range of FeLV-A/Glasgow-1 and FeLV-A/261env 
Species Cell line Glasgow-1 
(MOI 0.0035) 
Glasgow-1 
(MOI 0.00035) 
FeLV-A/261env 
(MOI 0.00011) 
Cat FEA ++/+++ +/++ +/++ 
CRFK +/++ nt +++ 
Human HeLa - - - 
HEK293 ++ - - 
Pig ST-IOWA - - - 
Guinea Pig 104C1 - - - 
Mouse M. dunni - - - 
Dog MDCK +++ +/++ - 
FeLV p27 ELISA: + > 4%; ++ > 10%; +++ > 20%; nt = not tested  
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6 Discussion 
In the present study we have characterized highly divergent FeLV-A/Glasgow-1 
variants from the experimentally FeLV-infected cat #261 by examining the viruses’ 
insertion sites, replication efficiency and host range. The FeLV variants arose during 
a long-term (8.5 years) FeLV-FIV-infection and were of interest due to their high 
degree of mutations in the env gene (89-92% amino acid identity of the variants to 
FeLV-A/Glasgow-1) and LTR (96-98% amino acid identity of the variants to FeLV-
A/Glasgow-1). In addition, the virus loads of the progeny variants were significantly 
higher in vivo compared to the original inoculation strain (Helfer-Hungerbuehler et al., 
2010).  
 
6.1 Integration sites 
The occurrence of malignant diseases in FeLV infection occurs over a time course of 
several weeks to a few years after virus exposure (Hoover and Mullins, 1991, 
Hartmann, 2011, Hofmann-Lehmann et al., 1997, Tsatsanis et al., 1994, Beatty, 
2014). FeLV usually does not carry oncogenes; rather insertional mutagenesis has 
been identified as a crucial factor in the development of lymphomas. The onset of 
those malignancies is associated with several mechanisms of insertional 
mutagenesis. One of these mechanisms is insertional activation of oncogenes at the 
sites of proviral integration either by replacing the endogenous promoter with the very 
active promoter contained in the 3’ LTR U3 region or by enhancing endogenous 
promoter activation by the enhancer element also part of the same U3 region (see 
also Figure 1 and Figure 5). This oncogenic potential may also affect genes at 
greater distance up to 300 kb up and down stream of the integration site (Lazo et al., 
1990, Johnson et al., 2005, Kool and Berns, 2009) and is even greater when tandem 
repeats in the 3’ LTR U3 are found (Chandhasin et al., 2005b). Although no enhancer 
repeats were detected in the LTR variants of cat #261, several mutations in the 
enhancer region were identified. Thus, characterization of these variants and their 
integration sites might provide further insight into viral enhancer mechanisms. 
Another mechanism works by disrupting genes by proviral insertion; this is especially 
the case, if tumor suppressor genes are affected. Because of these mechanisms, 
analysis of insertion sites has been useful as a tool to identify genes, which are 
associated with malignancies. 
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In the present study we aimed to identify genes involved in FeLV-A/Glasgow-1-
induced lymphomas in two experimentally infected cats, cat #261 and cat #67, by 
performing integration site analysis using genome walking. Both cats were kept 
under similar barrier conditions. As previously described the cat #261 was a special 
case as it was co-infected with FeLV and FIV and had a B-cell lymphoma. Therefore, 
we also analyzed the insertion sites in cat #67 that developed a FeLV-A associated 
T-cell lymphoma after three years of viremia; the latter is an infection outcome we 
have observed in several FeLV-A/Glasgow-1 mono-infected cats (Hofmann-Lehmann 
et al., 1995, Helfer-Hungerbuehler et al., 2015). 
Interestingly, the integration sites found in the present study in the two FeLV-
A/Glasgow-1 infected cats were all distinct from common integration sites previously 
described in FeLV-infected cats (Table 5). Three different databases (RTCGD, TAG, 
COSMIC) were queried to assess whether the genes close to the integration sites 
had already been described in tumorigenic processes in humans or mice. From the 
list of identified insertion sites in cat #261 and #67, there were some insertions near 
genes with oncogenic potential (NKX2-1, NKX2-2, DRD2) and genes involved in 
apoptosis (PUS10, NAIF1) or with repressor function (GFI1B, PAX1).  
 
In the following all genes within proximity of the detected integration sites and their 
function in humans and mice are discussed beginning with the ones determined in 
cat #261 followed by those in cat #67. For each cat, the genes are listed and 
reviewed according to their potential importance in tumorigenic processes according 
to the literature and our opinion. 
In cat #261 we found integrations in-between genes (NKX-2-1 and MBIP, DRD2 and 
TMPRSS5, TLR5 and SUSD4) and integrations within two genes (PUS10 and 
SNX25). 
NKX2-1 is also known as thyroid transcription factor 1 (TTF-1). In one of the queried 
databases it showed up as a tumor associated gene and is known as a molecular 
marker in human lung cancer and useful in identifying the origin tissue of metastases 
(Holzinger et al., 1996). The role of NKX2-1 in cancer pathogenesis is very complex, 
because it can act as both, a tumor suppressor or oncogene (Mu, 2013). An 
overexpression of NKX2-1 is found in about 12% of cases of human lung 
adenocarcinoma (Weir et al., 2007), but low NKX2-1 expressions in those tumors are 
generally associated with poor prognosis (Barletta et al., 2009). In addition, in a study 
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using a mouse model of lung adenocarcinoma, a loss of mouse NKX2-1 promoted 
metastasis (Winslow et al., 2011). MBIP is located right next to NKX2-1 and has also 
been mentioned in association with an increased thyroid cancer risk; however, the 
later may also be due to its proximity to NKX2-1 (Porcu et al., 2013). MBIP is 
involved in chromatin organization and is a protein kinase inhibitor. 
DRD2 encodes the D2 subtype of the dopamine receptor. It was found, that DRD2 is 
upregulated in some cancers of the pituitary gland (Wood et al., 1991) and of the 
gastrointestinal tract (Mu et al., 2017). In one study an upregulation of DRD2 in 
human pancreatic cancer was observed and it was reported that treating xenograft 
mice with DRD2 antagonist reduced proliferation and migration of tumor cells 
(Jandaghi et al., 2016). 
TLR5 plays a role in pathogen recognition, specifically the flagellin of bacteria and 
mobilizes the nuclear factor NF-kB (Smith and Ozinsky, 2002, Zeng et al., 2006). NF-
kB has ambiguous effects concerning cancer development and treatment. An 
activation of NF-kB might be beneficial in fighting cancer, because it enhances the 
expression of genes, which are helping in attracting and activating neutrophils, 
natural killer (NK) cells and dendritic cells. These cells play important roles in 
immune responses against pathogens and tumor cells (Yang et al., 2016). Thus, toll 
like receptor agonists might have a potential as therapeutics for cancer (Connolly and 
O'Neill, 2012). But there are also adverse effects by activating NF-kB in tumor cells. 
NF-kB helps in recruiting pro-inflammatory cytokines, thus creating a tumorigenic 
microenvironment. Additionally, NF-kB activation in tumor cells stimulates cell 
proliferation, prevents apoptosis, regulates tumor angiogenesis, promotes tumor 
metastasis and even has influence on the energy metabolisms of tumor cells (Xia et 
al., 2014). It would be interesting to find out whether an overexpression of TLR5 
caused by the enhancer of FeLV-U3 region would lead to a pro-tumorigenic 
environment or aggravate already existing tumorigenic diseases.  
SUSD4 was shown to function as a complement inhibitor and was also found 
activated in tumor infiltrating cells in different cancers (Holmquist et al., 2013). 
Complement activation can either kill cancer cells or create an inflammatory 
environment, which promotes cancer progression (Donin et al., 2003, Markiewski et 
al., 2008), thus the role of SUSD4 in cancer is not yet fully understood. One study 
showed that an expression of SUSD4 was associated with a better prognosis for 
patients suffering from breast cancer (Englund et al., 2015).  
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PUS10 is involved in apoptosis as it has been identified as a modulator of TRAIL-
induced cell death using RNA interference (RNAi) library screening (Aza-Blanc et al., 
2003). TRAIL (TNF-related apoptosis-inducing ligand) is a cytokine, which binds to 
the death receptors DR4 and DR5 leading to an activation of caspase-8, which 
cleaves full-length BID (BH3 interacting domain death agonist) to its truncated form 
(tBID). tBID is a mediator of mitochondrial damage and in this process cytochrome c 
is released, which triggers further caspases, such as caspase-9 and caspase-3, 
inducing apoptosis primarily in tumor cells. In one study (Park et al., 2009) it was 
shown that a down regulation of PUS10 by RNAi in HeLa cells led to a decrease in 
TRAIL-induced cell death. Our results showed that the integration of the provirus took 
place in the third intron of PUS10. It is unknown whether this insertion would interfere 
with the proper transcription and expression of the gene, for example through intron 
retention (Jacob and Smith, 2017). Intron retention occurs through aberrant splicing 
and may lead to premature termination codons and thus loss of function. This is 
especially undesired when tumor suppressors are affected (Jung et al., 2015). 
Assuming that this mechanism affects the gene PUS10, the loss of its function may 
lead to a growth advantage of the infected cells, since the apoptotic cycle is not 
properly induced.  
SNX25 plays a role in cellular trafficking and signaling and may modulate TGF-β 
signaling via TGF-β receptors (Hao et al., 2011, Mas et al., 2014). The insertion of 
the proviral FeLV DNA in exon 7 of this gene may have disrupted its function. 
However, due to the broad spectrum of functions of this gene, a connection to 
tumorigenesis is difficult to pinpoint.  
TMPRSS5 encodes a protein that is part of the serine protease family. Those 
proteases are widely spread in the mammalian central nervous system (Mitsui et al., 
2008). The expression of TMPRSS5 was mainly found in the spinal cord and 
astrocytes of mice (Yamaguchi et al., 2008). To the best of our knowledge it has not 
been described as an oncogene.  
 
In cat #67 integration sites were all found in-between genes (GFI1B and GTF3C5, 
FAM102A and NAIF1, NKX2-2 and PAX1) and not within genes.  
GFI1B is a transcription factor and required for hematopoiesis. It is a homolog to 
GFI1, which was described as a proviral integration site in T-cell lymphomas in rats 
caused by the gammaretrovirus Moloney murine leukemia virus (Gilks et al., 1993, 
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Kim et al., 2003). GFI1 can also cooperate with the oncogenes c-myc or pim1 and 
leads to an accelerated onset of lymphomagenesis when overexpressed (Schmidt et 
al., 1998). But also adverse effects of GFI1B are described, so it can act as an 
important repressor of genes, which function as tumor suppressors (Anguita et al., 
2017). Among those genes are also myc and myb (Rodriguez et al., 2005). GFI1B 
seems also to play a key role in T-lymphopoiesis. Xu and Kee (Xu and Kee, 2007) 
showed in their study that an ectopic expression of Gfi1b could stop proliferation and 
survival of T-cell lymphomas in culture obtained from E2A (a transcription factor) 
deficient mice via repression of GATA3 (transcription factor). So, a loss of its 
repressor function might lead to malignancies. Due to all those facts it would be 
interesting to investigate whether GFI1B is a preferred integration site in T-cell 
lymphomas in FeLV-positive cats or otherwise involved in the regulation of T-cell 
lymphomas in the species cat. GTF3C5 is found next to GFI1B and is involved in 
RNA polymerase III-mediated transcription (Dumay-Odelot et al., 2007).  
NKX2-2 is encoding a transcription factor and is involved in development of the 
central nervous system and also in glial and neuroendocrine differentiation (Briscoe 
et al., 1999, Wang et al., 2009). NKX2-2 seems to be a target gene for oncogenic 
transformation in Ewing’s sarcoma (Smith et al., 2006) and has been suggested as 
an immune histochemical marker to differentiate this tumor from other round cell 
tumors (Hung et al., 2016).  
PAX1 is part of the paired box (PAX) family, which all encodes transcription factors. 
PAX1 was found silenced in ovarian and cervical cancer (Su et al., 2009, Huang et 
al., 2010) and thus is assumed to act as a possible tumor suppressor and is 
considered a promising biomarker in the diagnosis of malignant and premalignant 
endometrial lesions (Nikolaidis et al., 2015, Chen et al., 2016). 
NAIF1 is involved in apoptosis. It was found down regulated in various human 
cancers as in non-small cell lung cancer, gastric cancer and prostate cancer (Zhao et 
al., 2015, Yang et al., 2015, Fu and Cao, 2015). FAM102A also known as EEIG1 
(early estrogen-induced gene 1) is found next to NAIF1. It might be involved in 
estrogen action and bone homeostasis (Choi et al., 2013).  
 
The two cats #261 and #67 did not share any integration sites; this might be due to 
distinctive characteristics of the lymphomas. It was reported in a study by Bolin and 
Levy (Bolin and Levy, 2011) that in other FeLV-infected cats with T-cell lymphomas 
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predominantly insertion near c-myc, flvi-2, fit-1 or pim-1 could be observed but not in 
multicentric, non-T-cell tumors, in which flvi-1 was identified as CIS (Athas et al., 
1995a, Levesque et al., 1990). Although, cat #67 had the typical T-cell lymphoma no 
integration site near the already described CIS was found, but a new promising site 
near GFI1B, worth investigating. Cat #261 had not the typical FeLV-A T-cell 
lymphoma but a B-cell lymphoma and therefore the integration sites might be 
different from common integration sites in FeLV-infected cats. Nevertheless, some 
sites found in cat #261 might also have relevance in oncogenesis and might be of 
interest in further studies.  
 
To the best of our knowledge this is the first study to document insertion sites of 
FeLV-A/Glasgow-1 and its variants. Overall, the most interesting genes in 
association with lymphoma development in these two cats were in our eyes GFI1B, 
NAIF1, NKX2-2 and PAX1 in cat #67 and NKX2-1 and DRD2 in cat #261. To assess 
whether those genes played a key role in tumorigenesis in the tested two cats, 
further investigation, for example with northern blot would bring more insights into 
whether these genes are potentially up or down regulated. Southern analysis of 
genomic DNA from tumor tissue could provide information on the presence of 
clonally integrated FeLV proviruses, indicative of their involvement during 
tumorigenesis. Thus, in order to assess the importance of the found insertion sites, 
southern blot analysis could be performed. 
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6.2 Replication efficiency 
The high abundance of the FeLV progeny variants and a decreased abundance of 
FeLV-A/Glasgow-1 in cat #261 led to the hypothesis that the variants might have a 
higher replication efficiency than FeLV-A/Glasgow-1 (Helfer-Hungerbuehler et al., 
2010). Our in vitro findings do not clearly support this hypothesis. In contrast, the 
tested variants showed generally lower replication efficiency in FEA cells compared 
to the original challenge virus FeLV-A/Glasgow-1 with one exception. This 
observation was more evident when assessing the FeLV p27 antigen levels in the 
cell culture supernatant and to a lesser degree when quantifying viral RNA. Only one 
of the tested variants, 261L3, reached replication levels similar to that of FeLV-
A/Glasgow-1, not during the early phase after transfection but several days later.  
The other LTR variants generally showed lower replication capacity in FEA cells 
compared to FeLV-A/Glasgow-1. In order to confirm that this change in replication 
efficiency was not due to mutational changes in the LTR acquired during the in vitro 
experiment, the LTRs of FeLV-A/Glasgow-1 and its progenies were re-sequenced at 
the end of the replication study and the sequence integrity was ensured.  
Some LTR variations are associated with a particular disease outcome. Usually, 
tumor-derived FeLV proviruses collected from natural occurring T-cell lymphomas in 
cats contain one or more copies of the enhancer (Fulton et al., 1990, Rohn and 
Overbaugh, 1995, Chandhasin et al., 2004). A particular LTR was found to be 
common in non-T-cell, non-B-cell lymphoma of the spleen with a single enhancer but 
with a 21-bp tandem triplication beginning 25 bp downstream of the enhancer (Athas 
et al., 1995b). In another study a 47-bp tandem triplication in the upstream region of 
the enhancer was reported that caused myelodysplastic syndrome (MDS) in 41% of 
the cats experimentally infected with a virus clone carrying this 3 tandem direct 
repeats; some of these cats eventually developed acute myeloid leukemia (AML) 
(Hisasue et al., 2009). However, samples for this study describing sequence repeats 
were taken from naturally infected cats with AML or MDS and it is not clear, whether 
the triplication occurred de novo in each of the naturally infected cats or alternatively 
the cats with AML or MDS had all been infected with a virus strain containing the 
mutation.  
All LTRs of the progeny viruses described in this study differed remarkably from the 
LTR of the original strain FeLV-A/Glasgow-1, but no additional copies of the 
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enhancer nor other sequence repeats were found and the LTR recombinants did not 
displayed replication advantage tested on FEA cells. It is difficult to pinpoint the 
difference in replication efficiency to single mutations in the LTR variants. For 
example, the variant 261L1 showed mutations in every nuclear protein-binding site, 
but the replication efficiency was not widely different from those of other variants. 
Overall, all variants share two specific mutations; one occurred in the enhancer 
element NF1 and the other one 15 bp upstream of the TATA box, which is part of the 
core promoter sequence (see Figure 5). Interestingly, the transition from G to A in the 
location 15 bp upstream of the TATA box was also seen in the sequence of FeLV-
C/Sarma, a virus strain that was associated with aplastic anemia in cats (Riedel et al., 
1986, Riedel et al., 1988, Tailor et al., 1999, Quigley et al., 2000).  
The difference in replication efficiency was particularly pronounced when comparing 
the env-variant with the prototype FeLV-A/Glasgow-1. The envelope protein is 
particularly crucial for receptor interaction and cell entry. Every FeLV subgroup uses 
specific host receptors related to differences in the env due to recombination and 
mutations in this gene (Mendoza et al., 2006, Shalev et al., 2009, Takeuchi et al., 
1992). Therefore, the mutation in env protein preliminary determines disease 
outcome due to tissue tropisms by way of receptor binding. However, Chandhasin et 
al. showed that the recombination of 61E/945SL, which contained the env and 3’ LTR 
of FeLV-945 in the FeLV-A/61E backbone, not only induced another type of 
lymphoma but had a small but statistically significant replicative advantage in FEA 
cells over the 61E/945L recombinant, which only contained the mutated LTR but not 
env of strain 945 (Chandhasin et al., 2005a). Thus, mutations in env predominantly 
alter disease spectrum but also might provide the virus with a replication advantage. 
However, the opposite is also possible: mutations in the receptor binding sites may 
lead to mismatches that interfere with the binding of the receptor and the cell entry 
may thus be impeded or even impossible. A less efficient cell entry decreases the 
efficiency of viral replication. Even though the env variant was still able to infect feline 
cell lines in our study, viral RNA loads and p27 antigen levels of the progeny variants 
were lower compared to FeLV-A/Glasgow-1 in FEA cells. There are several 
mutations altering amino acid sequences in the env of the variants as shown in 
Figure 4. Important to mention are alterations found in two variable regions (VRA and 
VRB) within the receptor-binding domain (RBD), in the C2 loop domain and the 
proline-rich region. VRA and VRB define the specificity for receptor binding (Boomer 
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et al., 1997, Bolin et al., 2011), thus the mutations and especially the addition of 
amino acids in VRB might have led to a decreased receptor affinity. The C2 loop is 
part of the C-terminal region of the FeLV SU, which forms a second RBD in addition 
to the RBD of the N-terminal region containing VRA and VRB. Even though the C2 
loop domain varies naturally between FeLV subgroup env genes (Rey et al., 2008b) 
too many mutations might lead to loss of receptor binding function. The proline-rich 
region seems not to take part in receptor recognition (Gray and Roth, 1993) but is an 
important link between the N-terminal region and the C-terminal region (Barnett et al., 
2001, Fass et al., 1997) and is said to contribute to viral infectivity (Lavillette et al., 
2002). Not only did alteration of the amino acids in the PRR region of the env variant 
occur, but also a loss of three consecutive amino acids. This might also have played 
a role in the decreased infectivity of the env variant of cat #261 in FEA cells.  
We cannot exclude the possibility that our variants may have behaved differently if 
using other cell lines. For example, in a study by Athas et al. the variant 61g945L 
was tested on FEA cells and on a human malignant hematopoietic progenitor cell line 
termed K-562 cells, and was observed 4.2 fold more active in K-562 cells than in 
FEA cells (Athas et al., 1995b, Nishigaki et al., 1997). And in a study by Chandhasin 
et al. the examined variants were tested on FC6.BM cells, 3201 cells in addition to 
FEA cells. It was observed that one of the variants showed a statistically significant 
replicative advantage in FEA cells but did not in the other feline cell lines, when 
compared to another variant (Chandhasin et al., 2005a). We found some evidence 
for this in the host range experiment. While FeLV-A/261env produced similar levels 
of p27 antigen in the FEA cells in this study as compared to FeLV-A/Glasgow-1, the 
env variant produced higher p27 antigen levels than the prototype virus in CRFK 
cells. 
Why the progeny variants were more abundant in the tissues of cat #261 is thus not 
quite clear at present from our in vitro results. The vaccination against FeLV and the 
following regressive course of the FeLV infection after inoculation with the strain 
FeLV-A/Glasgow-1 might have provided the immune system of cat #261 with an 
initial protection against FeLV-A/Glasgow-1, which may be in agreement with the 
persistently high anti-FeLV antibodies that were detected in cat #261 (Helfer-
Hungerbuehler et al., 2010). The advanced stage of the FIV infection later on may 
have been relevant to the course of disease progression; first a progressive FIV 
infection leads to an immune dysfunction by depleting CD4+ T lymphocytes in 
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peripheral blood, which possibly facilitated the reoccurrence of FeLV in cat #261 
(Pedersen et al., 1989, Magden et al., 2011, Ravi et al., 2010, Hoffmann-Fezer et al., 
1992, Hofmann-Lehmann et al., 1997). Second, it is suggested that during the course 
of an FIV infection a loss in immune surveillance function occurs (Callanan et al., 
1992, Callanan et al., 1996, Hartmann, 2011, Terry et al., 1995, Magden et al., 2011). 
This might have given an “escape” advantage to the variants compared to the 
original inoculation strain FeLV-A/Glasgow-1, which was already “known” to the 
immune system.  
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6.3 Importance of co-infections with other cancer associated 
viruses 
6.3.1 FIV co-infection in cat #261 
Interestingly, the cat #261 developed a multicentric monoclonal B-cell lymphoma 
(Helfer-Hungerbuehler et al., 2010). The co-infection of FIV in cat #261 might also 
have played an important role in the development of this tumor phenotype (large B-
cell lymphoma), which was associated with FIV infection (Callanan et al., 1996, Terry 
et al., 1995, Wang et al., 2001, Gabor et al., 2001). Early on an association between 
FIV and an increased incidence of neoplasia was assumed (Callanan et al., 1992, 
Gabor et al., 2001, Magden et al., 2011, Pedersen et al., 1989, Terry et al., 1995, 
Poli et al., 1994, Shelton et al., 1990). But only in few cases a direct oncogenic role 
of FIV could be shown in the emergence of neoplasia (Beatty et al., 1998, Beatty et 
al., 2002, Wang et al., 2001). It is thought that the mechanism of tumorigenesis 
occurs in a more indirect way (Callanan et al., 1992, Callanan et al., 1996, Hartmann, 
2011, Terry et al., 1995, Magden et al., 2011) by an impaired immune surveillance 
and failure to eliminate neoplastic cells due to vast expansion of lymphoid cells. 
Studies by Callanan et al. (Callanan et al., 1992, Callanan et al., 1996) showed an 
increased B cell proliferation in FIV infected cats (Flynn et al., 1994). They suggested 
that would lead to more opportunities of malignant transformation. The indirect 
mechanisms of FIV providing a greater pool of B cells in combination with an 
immunosuppression might have facilitated the transformation of a single B-cell - with 
or without the assistance of FeLV - thereby leading to a diffuse monoclonal B-cell 
lymphoma in cat #261 (Helfer-Hungerbuehler et al., 2010). 
 
6.3.2 Other cancer associated viral co-infections in humans and cats 
Co-infections with other viruses are also associated with a higher likelihood of cancer 
development. For example, the two human gammaherpesviruses (GHV), Epstein-
Barr virus (EBV) and Kaposi’s sarcoma-associated virus (KSHV), were associated 
with specific kinds of lymphomas in HIV positive humans (Thompson et al., 2004, 
Gloghini et al., 2013). Recently a feline gammaherpesvirus was discovered, which is 
also under investigation for a possible tumorigenic potential especially in FIV infected 
cats (Troyer et al., 2014, Beatty et al., 2014, Tateno et al., 2017, McLuckie et al., 
2017, Kaye et al., 2016, McLuckie et al., 2018). Given the discovery of this new virus, 
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both cats used in this study (#261 and #67) were retrospectively tested for feline 
gammaherpesvirus by	real-time PCR (Troyer et al., 2014): both cats tested negative 
for the feline gammaherpesvirus at the time of necropsy (data not shown).  
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6.4 Host Range 
Different subgroups of FeLV bind to specific receptors, which may be ecotropic, as is 
the case with the FeLV-A receptor THTR1, or amphotropic, as is the case with the 
FeLV-B receptor Pit1 and Pit2 (Anderson et al., 2001). The host range experiment of 
this study was performed in order to review the env-variant to provide more 
information whether the mutations of this variant expand the ecotropic host range of 
FeLV-A/Glasgow-1.  
The replication efficiency of the env-variant in FEA cells was lower compared to that 
of FeLV-A/Glasgow-1. Thus, a titration experiment was conducted prior to the main 
host range experiment to yield virus preparations with similar infectivity. For the 
FeLV-A/261env variant a virus stock could be produced in FEA cells; the maximal 
achievable virus concentration was lower than that of FeLV-A/Glasgow-1. In 
consequence, the stock solution of FeLV-A/Glasgow-1 had to be diluted tenfold to 
approximately match the infectious dose of the env-variant. Moreover, FeLV-
A/Glasgwo-1 was also tested undiluted, as the low MOIs might have led to a loss of 
infectivity. Using a virus concentration kit might have been an option to concentrate 
the virus. We refrained from using this option for the present study because of 
previous poor results caused by massive loss of viral infectivity during the procedure.  
In accordance to previous reports FeLV-A/Glasgow-1 could not infect HeLa, ST-
IOWA, 104C1 and M. dunni cell lines (Nakata et al., 2003, Moser et al., 1998, Shalev 
et al., 2009). This also applied to the variant FeLV-A/261env, which was unable to 
infect these cell lines.  
Nakata et al. showed that an infection of HEK293 cells with FeLV-A/Glasgow-1 was 
possible but with a very low titer of expression (4,050 focus forming units/ml of lacZ 
pseudotype) (Nakata et al., 2003). This observation applies to our findings, where 
FeLV-A/Glasgow-1 could successfully infect HEK293 cells using the stock solution, 
while the tenfold dilution and the stock solution of FeLV-A/261env failed to induce a 
productive infection due to low MOIs. 
The feline cell lines (FEA and CRFK), were, as expected, infected by both virus 
strains. This indicates no difference in the host cell spectrum using feline cells. 
Remarkably, the infection of FEA cells showed no differences in p27 antigen levels 
when using virus infection and comparable MOIs of the different viruses, while the 
env variant produced higher p27 antigen levels in CRFK cells than the FeLV-
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A/Glasgow-1 virus. This indicates a difference between the original challenge strain 
FeLV-A/Glasgow-1 and its progeny FeLV-A/261env in replication efficiency in CRFK 
cells.  
MDCK cells were shown to be susceptible to FeLV-B but not to FeLV-A (Nakata et al., 
2003, Shojima et al., 2006). In an older study a long-term infection of MDCK cells 
with FeLV could be induced but the paper did not state whether the virus used in the 
experiment is of the subgroup A or B (Essex et al., 1972). Unexpectedly, in our study 
we observed an infection of MDCK cells with FeLV-A/Glasgow-1. An infection was 
also observed with the lower virus titer of FeLV-A/Glasgow-1 but not with the 
recombinant FeLV-A/261env variant. In order to confirm the exclusive presence of 
dog cells in the MDCK cells and absence of any cat cell contamination or cell-line 
confusion, a feline albumin gene PCR was performed (Kessler et al., 2009), which 
recognizes cells of feline origin. No feline albumin could be detected in the MDCK 
cells. The possibility that the MDCK cell line used in this study differs from the one 
used in other studies is not entirely excluded, since the origin of the cell line could not 
be traced anymore.  
Finally, the result of the infection of the MDCK and also of the CRFK cell lines might 
indicate a difference between the virus strain FeLV-A/Glasgow-1 and the 
recombinant env-variant. A closer look to receptor usage might bring more light into 
this matter. An interference assay (Sarma and Log, 1973) could be carried out to 
verify whether the recombinant env variant truly belongs to the FeLV subgroup A.  
Even though some further experiment could provide more in-depth information about 
the recombinant variant FeLV-A/261env, we conclude that the mutational changes in 
this variant did not expand the ecotropic host range of the FeLV subgroup A.   
50 
 
6.5 Conclusions 
To the best of our knowledge, this is the first time that insertion sites of FeLV-
A/Glasgow-1 and progeny viruses thereof are described. The integration sites found 
for FeLV-A/Glasgow-1 in cat #261 and its variants, as well as the integration sites in 
cat #67 were not described in cats so far. Several of the identified genes, where the 
insertions were located (particularly GFI1B, NAIF1, NKX2-2, PAX1, NKX2-1), are of 
interest due to their role in the apoptosis cycle and relation to tumorigenesis 
recognized in other species. A homolog of one of these genes (GFI1) had been 
recognized earlier as an integration site of the gammaretrovirus Moloney murine 
leukemia virus in a rat with a T-cell lymphoma. The integration sites in the two 
investigated cats, one with a B-cell lymphoma and a FIV coinfection (cat #261) and 
one only FeLV-A/Glasgow-1 infected and with a T-cell lymphoma, were distinct. 
Further studies will be necessary to investigate the importance of these insertion 
sites in the pathogenesis of FeLV-associated lymphoma. 
In the immunodeficient cat #261 highly divergent and in vivo dominant FeLV-variants 
developed during the course of FeLV-infection. Some of these variants were further 
investigated for in vitro replication capacity and host range. The host range 
experiment of the envelope variant showed the ecotropic limit, which is typical for 
FeLV-A subgroups, so that the mutational changes in the envelope did not expand 
the host range, like it would be seen in FeLV-B subgroups. Despite the higher loads 
of the FeLV variants in most of the tissues investigated of cat #261, the replication 
efficacies of the variants were largely lower in FEA cells compared to the original 
inoculation strain FeLV-A/Glasgow-1. These findings though cannot exclude possible 
cell-type specific behaviors of the variants in other cell lines. However, the 
abundance of the progeny variants in the tissue of cat #261 in comparison of the 
original inoculation strain FeLV-A/Glasgow-1 might be closer attributed to the co-
infection with FIV than a mutational increased viral fitness of the variants. Thus, it is 
our hypothesis that the variants that developed during the course of the infection in 
the highly immunosuppressed, CD4+ depleted cat #261 became predominant due to 
their potential evasion to the immune system. 
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Feline leukemia virus strain Glasgow-1, complete genome 
GeneBank: KP728112.1  
TGAAAGACCCCCTACCCCAAAATTTAGCCAGCTACTGCAGTGGTGTCATTTCACAAGGCATGGAAAATTA 
CTCAAGTATGTTCCCATGAGATATAAGGAAGTTAGAGGCTAAAACAGGATATCTGTGGTTAAGCACCTGG 
GCCCCGGCTTGAGGCCAAGAACAGTTAAACCCCGGATATAGCTGAAACAGCAGAAGTTTCAAGGCCGCTG 
CCAGCAGTCTCCAGGCTCCCCAGTTGACCAGAGTTCGACCTTCCGCCTCATTTAAACTAACCAATCCCCA 
CGCCTCTCGCTTCTGTGCGCGCGCTTTCTGCTATAAAACGAGCCATCAGCCCCCAACGGGCGCGCAAGTC 
TTTGCTGAGACTTGACCGCCCCGGGTACCCGTGTACGAATAAACCTCTTGCTGATTGCATCTGACTCGTG 
GTCTCGGTGTTCCGTGGGCACGGGGTCTCATCGCCGAGGAAGACCTAGTTCGGGGGTCTTTCATTTGGGG 
GCTCGTCCGGGATAGAGACCCCCAACCCCCGGGACCACCGACCCACCATCAGGAGGTAAGCTGGCCGGCG 
ACCATACCTGTTGTCCTTGTATAAGTGTCTCTGTCAATTGATCTGATTTTGGCGGTGGGATCGAAGGAGC 
TGACGAGCTCGTACTTCGCCCCCGCAACCCTGGAAGACGTTCCACGGGTGTCTGATGTCTGGAGCCTCTA 
GTGGGACAGCCATTGGGGCTCATCTGTTTGGGGTCTCACCTGAATACAGGGTGTTGATCGGAGACGAGGG 
AGCCGGACCCTCAAGGTCTCTTTCTGAGGTTTCATTTTCGGTTTGGTACCAAAGCCGCGCGGCACGTCTT 
GTCATTTTTTGTCTGGTTGCGTCTTTTCTTGTCCCTTGTCTAACCTTTTTAATTGCAGAAACCGTCATGG 
GCCAAACTATAACTACCCCCTTAAGCCTCACCCTTGATCACTGGTCTGAAGTCCGGGCACGAGCCCATAA 
TCAAGGTGTCGAGGTCCGGAAAAAGAAATGGATTACCTTATGTGAGGCCGAATGGGTGATGATGAATGTG 
GGCTGGCCCCGAGAAGGAACTTTTTCTCTTGATAGCATTTCCCAGGTTGAAAAAAAGATCTTCGCCCCGG 
GACCATATGGACACCCCGACCAAGTTCCTTACATTACTACATGGAGATCCTTAGCCACAGACCCCCCTTC 
GTGGGTTCGTCCGTTCCTACCCCCTCCTAAACCTCCCACACCCCTCCCTCAACCTCTTTCGCCGCAGCCC 
TCCGCCCCTCTTACCTCTTCCCTCTACCCCGTTCTCCCCAAGCCAGACCCCCCCAAACCGCCTGTGTTAC 
CGCCTGATCCTTCCTCCCCTTTAATTGATCTCTTAACAGAAGAGCCACCTCCCTATCCGGGGGGTCACGG 
GCCACCGCCATCAGGTCCTAGGACCCCAACCGCTTCCCCGATTGCAAGCCGGCTAAGGGAACGACGAGAA 
AACCCTGCTGAAGAATCGCAAGCCCTCCCCTTGAGGGAAGGCCCCAACAACCGACCCCAGTATTGGCCAT 
TCTCAGCTTCAGACTTGTATAACTGGAAGTCGCATAACCCCCCTTTCTCCCAAGATCCAGTGGCCCTAAC 
TAACCTAATTGAGTCCATTTTAGTGACGCATCAACCAACCTGGGACGACTGCCAGCAGCTCTTGCAGGCA 
CTCCTGACAGGCGAAGAAAGGCAAAGGGTCCTTCTTGAGGCCCGAAAGCAGGTTCCAGGCGAGGACGGAC 
GGCCAACCCAACTACCCAATGTCATTGACGAGACTTTCCCCTTGACCCGTCCCAACTGGGATTTTGCTAC 
GCCGGCAGGTAGGGAGCACCTACGCCTTTATCGCCAGTTGCTATTAGCGGGTCTCCGCGGGGCTGCAAGA 
CGCCCCACTAATTTGGCACAGGTAAAGCAGGTTGTACAAGGGAAAGAGGAAACGCCAGCAGCATTTTTAG 
AAAGATTAAAAGAGGCTTATAGAATGTACACTCCCTATGACCCTGAGGACCCAGGGCAAGCGGCTAGTGT 
TATCCTATCCTTCATATACCAGTCTAGCCCAGATATAAGAAATAAGTTACAAAGGCTAGAAGGCCTACAA 
GGGTTCACCCTATCTGATCTGCTAAAAGAGGCAGAAAAGATATACAACAAAAGGGAGACCCCAGAGGAAA 
GGGAAGAAAGATTATGGCAGCGACAGGAAGAAAGAGATAAAAAGCGCCACAAGGAGATGACTAAAGTTCT 
GGCCACAGTAGTTGCTCAGAATAGAGATAAAGATAGAGAAGAAAGTAAACTGGGGGATCAAAGGAAAATA 
CCTCTGGGGAAAGACCAGTGTGCCTATTGCAAGGAAAAGGGGCATTGGGTTCGCGATTGCCCCAAACGAC 
CCAGGAAGAAACCCGCCAACTCCACTCTCCTCAACTTAGGAGATTAGGAGAGTCAGGGCCAGGACCCCCC 
CCCTGAGCCCAGGATAACCTTAAAAATAGGGGGGCAACCGGTGACTTTTCTGGTGGACACGGGAGCCCAG 
CACTCAGTACTGACTCGACCAGATGGACCTCTCAGTGACCGCACAGCCCTGGTGCAAGGAGCCACGGGAA 
GCAAAAACTACCGGTGGACCACCGACAGGAGGGTACAACTGGCAACCGGTAAGGTGACTCATTCTTTTTT 
ATATGTACCTGAATGTCCCTACCCGTTATTAGGGAGAGACCTATTAACTAAACTTAAGGCCCAAATCCAT 
TTTACCGGAGAAGGGGCTAATGTTGTTGGGCCCAGGGGTTTACCCCTACAAGTCCTTACTTTACAATTAG 
AAGAGGAGTATCGGCTATTTGAGCCAGAAAGTACACAAAAACAGGAGATGGACACTTGGCTTAAAAACTT 
TCCCCAGGCGTGGGCAGAAACAGGAGGTATGGGAATGGCTCATTGTCAAGCCCCCGTTCTCATTCAACTT 
AAGGCTACTGCCACTCCAATCTCCATCCGACAGTATCCTATGCCCCATGAAGCGTACCAGGGAATTAAGC 
CTCATATAAGAAGAATGCTAGATCAAGGCATCCTCAAGCCCTGCCAGTCCCCATGGAATACACCCTTATT 
ACCTGTTAAGAAGCCAGGGACCGAGGATTACAGACCAGTGCAGGACTTAAGAGAAGTAAACAAAAGAGTA 
GAAGACATCCATCCTACTGTGCCAAATCCATATAACCTCCTTAGCACCCTCCCGCCGTCTCACCCTTGGT 
ACACTGTCCTAGATTTAAAGGACGCTTTTTTCTGCCTGCGACTACACTCTGAGAGTCAGTTACTTTTTGC 
ATTTGAATGGAGAGATCCAGAAATAGGACTGTCAGGGCAACTAACCTGGACACGCCTTCCTCAGGGGTTC 
AAGAATAGCCCCACCCTATTTGATGAGGCCCTGCACTCAGACCTGGCCGATTTCAGGGTAAGGTACCCGG 
CTCTAGTCCTCCTACAATATGTAGATGACCTCTTGCTGGCTGCGGCAACCAGGACTGAATGCCTGGAAGG 
GACTAAGGCACTCCTTGAGACTTTGGGCAATAAGGGGTACCGAGCCTCTGCAAAGAAGGCCCAAATTTGC 
CTGCAAGAAGTCACATACCTGGGGTACTCTTTAAAAGATGGCCAAAGGTGGCTTACCAAAGCTCGGAAAG 
AAGCCATCCTATCCATCCCTGTGCCTAAAAACCCACGACAAGTGAGAGAGTTCCTTGGAACTGCAGGTTA 
CTGCCGGCTGTGGATTCCCGGTTTTGCCGAGCTCGCAGCCCCGCTATACCCTCTCACTCGACCAGGAACT 
CTGTTCCAGTGGGGAACAGAGCAACAATTGGCCTTCGAGAACATTAAAAAAGCCCTCTTGAGCTCCCCTG 
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CCCTGGGGTTGCCAGATATCACCAAGCCCTTTGAATTATTTATTGATGAGAGCTCAGGATTCGCGAAGGG 
GGTGTTAGTCCAAAAACTGGGACCCTGGAAAAGACCAGTTGCCTACCTATCAAAAAAACTGGATACAGTG 
GCATCTGGATGGCCCCCTTGTTTACGCATGGTTGCAGCCATCGCCATCCTAGTCAAGGATGCAGGGAAGC 
TAACCCTAGGACAGCCGCTAACTATCCTGACCTCTCACCCAGTTGAGGCACTCGTCCGACAGCCTCCAAA 
TAAATGGCTCTCTAATGCTAGAATGACTCATTACCAAGCTATGCTCCTCGATGCAGAGCGAGTCCATTTC 
GGGCCAACAGTCTCCCTTAACCCTGCTACCTTGCTCCCCCTCCCCAGTGGGGGAAACCACCACAACTGTC 
TCCAGATTTTAGCCGAGACCCATGGCACCAGACCCGACTTAACTGACCAGCCGTTGCCGGATGCAGACCT 
GACCTGGTACACGGATGGTAGCAGCTTCATCCGTAACGGCGAGAGAAAGGCTGGAGCCGCAGTAACAACC 
GAATCTGAGGTAATCTGGGCTGCTTCCCTCCCACCCGGAACGTCAGCCCAGCGAGCCGAACTGATTGCCC 
TGACCCAGGCACTAAAGATGGCAAAAGGTAAGAAGCTAACTGTCTATACGGACAGCCGATATGCCTTTGC 
TACAGCTCATGTACACGGGGAAATCTACAGGCGGCGGGGCCTACTAACTTCAGAAGGAAAAGAAATTAAA 
AATAAAAATGAAATCCTCGCCCTACTAGAGGCGTTATTCTTACCCAAAAGACTGAGTATCATCCATTGCC 
CGGGACACCAAAAAGGTGATAGTCCCCAGGCGAAAGGAAACAGATTAGCTGATGATACAGCAAAGAAAGC 
CGCCACAGAGACTCATTCATCACTAACCGTCTTACCCACTGAACTTATAGAGGGTCCCAAAAGGCCTCCA 
TGGGAATATGATGACAGTGATTTAGACCTTGTGCAAAAACTCGAAGCTCATTATGAGCCAAAAAGAGGTA 
CCTGGGAGTACCAAGGGAAAACTATAATGCCTGAAAAATACGCAAAGGAGTTGATTAGCCATCTGCATAA 
GTTAACACACCTCAGTGCTAGGAAAATGAAAACTTTATTAGAAAGAGAAGAAACTGGGTTTTACCTCCCT 
AACAGAGACTTACACCTCCGGCAAGTAACAGAGAGCTGCCGGGCATGTGCTCAAATCAACGCAGGAAAGA 
TAAAGTTTGGACCTGATGTAAGGGCCCGAGGCCGCCGGCCCGGAACACATTGGGAAGTAGACTTCACTGA 
AATCAAGCCAGGAATGTATGGATATAAATACCTCTTGGTGTTCATAGACACCTTCTCTGGCTGGGCCGAA 
GCTTACCCCGCCAAACATGAAACAGCAAAAGTTGTCGCCAAGAAACTCTTAGAAGAAATTTTTCCCCGCT 
ACGGGATCCCCCAGGTATTGGGTTCAGATAATGGACCCGCCTTTATCTCCCAGGTAAGTCAGTCTGTGGC 
CACCCTACTGGGGATTAATTGGAAGTTACATTGTGCATACCGACCCCAAAGTTCAGGTCAGGTAGAAAGA 
ATGAATAGATCAATTAAGGAGACTTTAACTAAATTAACGCTAGAAACTGGCTCTAAGGATTGGGTGCTCC 
TCCTGCCCCTGGTTTTATACCGGGTACGTAACACGCCGGGTCCCCACGGGTTAACTCCTTTTGAAATCCT 
GTACGGGGCACCCCCACCTATGGCTCACTTCTTTGATGCTGATATCTCTAGCTTCGCTACCTCCCCCACT 
ATGCAGGCACATTTACGCGCCCTGCAGCTGGTCCAAGAAGAGATCCGGAGACCTCTAGCGGCGGCCTACC 
AAGAAAAGCTCGAAACCCCGGTTGTGCCTCACCCCTTCAAACCAGGAGACTCCGTCTGGGTTCGGAGACA 
TCAAACCAAGAACCTCGAGCCACGGTGGAAAGGACCACATATCGTCCTCCTGACCACCCCCACAGCCTTA 
AAGGTAGACGGAGTTGCTGCCTGGATTCACGCCTCTCACGTGAAAGCTGCAGGACCAACCACCAATCAAG 
ACCTCTCGGACAGCCCCAGCTCAGACGATCCATCAAGATGGAAAGTCCAACGCACCCAAAACCCTCTAAA 
GATAAGACTCTCTCGTGGAACTTAGCGTTTCTGGTGGGGATCTTATTTACAATAGACATAGGAATGGCCA 
ATCCTAGTCCACACCAAATATATAATGTAACTTGGGTAATAACCAATGTACAAACTAACACCCAAGCTAA 
CGCCACCTCTATGTTAGGAACCTTAACCGATGCCTACCCTACCCTACATGTTGACTTATGTGACCTAGTG 
GGAGACACCTGGGAACCTATAGTCCTAAACCCAACCAATGTAAAACACGGGGCACGTTACTCCTCCTCAA 
AATATGGATGTAAAACTACAGATAGAAAAAAACAGCAACAGACATACCCCTTTTACGTCTGCCCCGGACA 
TGCCCCCTCGTTGGGGCCAAAGGGAACACATTGTGGAGGGGCACAAGATGGGTTTTGTGCCGCATGGGGA 
TGTGAGACCACCGGAGAAGCTTGGTGGAAGCCCACCTCCTCATGGGACTATATCACAGTAAAAAGAGGGA 
GTAGTCAGGACAATAGCTGTGAGGGAAAATGCAACCCCCTGGTTTTGCAGTTCACCCAGAAGGGAAGACA 
AGCCTCTTGGGACGGACCTAAGATGTGGGGATTGCGACTATACCGTACAGGATATGACCCTATCGCTTTA 
TTCACGGTGTCCCGGCAGGTATCAACCATTACGCCGCCTCAGGCAATGGGACCAAACCTAGTCTTACCTG 
ATCAAAAACCCCCATCCCGACAATCTCAAACAGGGTCCAAAGTGGCGACCCAGAGGCCCCAAACGAATGA 
AAGCGCCCCAAGGTCTGTTGCCCCCACCACCATGGGTCCCAAACGGATTGGGACCGGAGATAGGTTAATA 
AATTTAGTACAAGGGACATACCTAGCCTTAAATGCCACCGACCCCAACAAAACTAAAGACTGTTGGCTCT 
GCCTGGTTTCTCGACCACCCTATTACGAAGGGATTGCAATCTTAGGTAACTACAGCAACCAAACAAACCC 
CCCCCCATCCTGCCTATCTACTCCGCAACACAAACTAACTATATCTGAAGTATCAGGGCAAGGAATGTGC 
ATAGGGACTGTTCCTAAAACCCACCAGGCTTTGTGCAATAAGACACAACAGGGACATACAGGGGCGCACT 
ATCTAGCCGCCCCCAACGGCACCTATTGGGCCTGTAACACTGGACTCACCCCATGCATTTCCATGGCGGT 
GCTCAATTGGACCTCTGATTTTTGTGTCTTAATCGAATTATGGCCCAGAGTGACTTACCATCAACCCGAA 
TATGTGTACACACATTTTGCCAAAGCTGTCAGGTTCCGAAGAGAACCAATATCACTAACGGTTGCCCTTA 
TGTTGGGAGGACTTACTGTAGGGGGCATAGCCGCGGGGGTCGGAACAGGGACTAAAGCCCTCCTTGAAAC 
AGCCCAGTTCAGACAACTACAAATGGCCATGCACACAGACATCCAGGCCCTAGAAGAATCAATTAGTGCC 
TTAGAAAAGTCCCTGACCTCCCTTTCTGAAGTAGTCTTACAAAACAGACGGGGCCTAGATATTCTATTCT 
TACAAGAGGGAGGGCTCTGTGCCGCATTGAAAGAAGAATGTTGCTTCTATGCGGATCACACCGGACTCGT 
CCGAGACAATATGGCCAAATTAAGAGAAAGACTAAAACAGCGGCAACAACTGTTTGACTCCCAACAGGGA 
TGGTTTGAAGGATGGTTCAACAAGTCCCCCTGGTTTACAACCCTAATTTCCTCCATTATGGGCCCCTTAC 
TAATCCTACTCCTAATTCTCCTCTTCGGCCCATGCATCCTTAACCGATTAGTACAATTCGTAAAAGACAG 
AATATCTGTGGTACAGGCTTTAATTTTAACCCAACAGTACCAACAGATAAAGCAATACGATCCGGACCGA 
CCATGATTTCCAATTAAATGTATGATTCCATTTAGTCCCCAGAAAAAGGGGGGAATGAAAGACCCCCTAC 
CCCAAAATTTAGCCAGCTACTGCAGTGGTGTCATTTCACAAGGCATGGAAAATTACTCAAGTATGTTCCC 
ATGAGATATAAGGAAGTTAGAGGCTAAAACAGGATATCTGTGGTTAAGCACCTGGGCCCCGGCTTGAGGC 
63 
 
CAAGAACAGTTAAACCCCGGATATAGCTGAAACAGCAGAAGTTTCAAGGCCGCTGCCAGCAGTCTCCAGG 
CTCCCCAGTTGACCAGAGTTCGACCTTCCGCCTCATTTAAACTAACCAATCCCCACGCCTCTCGCTTCTG 
TGCGCGCGCTTTCTGCTATAAAACGAGCCATCAGCCCCCAACGGGCGCGCAAGTCTTTGCTGAGACTTGA 
CCGCCCCGGGTACCCGTGTACGAATAAACCTCTTGCTGATTGCATCTGACTCGTGGTCTCGGTGTTCCGT 
GGGCACGGGGTCTCATCGCCGAGGAAGACCTAGTTCGGGGGTCTTTCA 
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